新・血栓止血血管学　血管と血小板

出版社： 金芳堂
著者：
発行日： 2015-08-10
分野： 臨床医学：内科  >  血液
ISBN： 9784765316422
シリーズ： 新・血栓止血血管学
電子書籍版： 2015-08-10 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

7,040 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

7,040 円(税込)

購入する

商品紹介

本書は、最新の二光子顕微鏡による観察や細胞基盤型モデルにもとづく血栓の発生メカニズムなどをキャッチアップし、近年研究が著しく進んでいる血栓止血血管学の羅針盤となるべく編集された。また、血栓や止血についての理解は、血液の凝固因子の生化学的な作用だけでなく、血管の脈管形成や血管と神経の相互作用、血管と血液の物理的相互作用などの基礎的事実を踏まえてこそ進むと考える。そこで本書では、血小板と血管に着目した。血栓症と出血症の制圧のため、遺伝子から全身の脈管形成まで血管と血小板の動態を網羅した決定版である。

目次

  • 新・血栓止血血管学　血管と血小板

    ―目次―

    1部　血管
    　 1．血管病の分子病態：AVMを含むオーバービュー
    　 2．造血管幹細胞を維持する骨髄の微小環境（ニッチ）
    　 3．脈管形成（血管／リンパ管発生）
    　 4．神経と血管のワイアリング
    　 5．血管と血流の相互作用
    　 6．プロテアーゼ活性化受容体PAR
    　 7．血管新生
    　 8．動脈の構造と動脈硬化の病理
    　 9．メタボリック症候群と血栓症
    　 10．静脈血栓塞栓症の予防と治療
    　 11．末梢動脈閉塞症

    2部　血小板
    　 12．血小板と血栓：オーバービュー
    　 13．血小板産生のメカニズム
    　 14．血小板の超微細形態
    　 15．血小板機能と血流
    　 16．血小板反応とそのシグナル伝達機構
    　 17. 血栓形成制御とシミュレーション理論
    　 18. めでみる血栓形成過程：二光子顕微鏡の生体への応用
    　 19．先天性血小板異常症の今（先天性巨大血小板症を含む）
    　 20．ScramblaseとScott症候群
    　 21．von Willebrand病
    　 22．ADAMTS13
    　 23．TTPとaHUS
    　 24．ヘパリン起因性血小板減少症
    　 25．免疫性血小板減少症
    　 26．感染症と血小板
    　 27．白血球・血小板複合体（NETs）

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 止血機構と血栓症 オーバービュー

P.13 掲載の参考文献
1) 一瀬白帝. 緒言 : 21世紀の国民病 血栓症の制圧に向けて. 一瀬白帝編, 図説 血栓・止血・血管学-血栓症制圧のために-. 東京 : 中外医学社, 2005 ; 前付け.
 
2) Grutzendler J. Angiophagy : mechanism of microvascular recanalization independent of the fibrinolytic system. Stroke 2013 ; 44 (6 Suppl 1) : S84-S86.
 
3) Rivera J, Lozano ML, Navarro-Nunez L, et al. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica 2009 ; 94 : 700-711.
PubMed
4) Li Z, Delaney MK, O'Brien KA, et al. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 2010 ; 30 : 2341-2349.
PubMed
5) Mazepa M, Hoffman M, Monroe D. Superactivated platelets : thrombus regulators, thrombin generators, and potential clinical targets. Arterioscler Thromb Vasc Biol 2013 ; 33 : 1747-1752.
PubMed
6) Suzuki J, Umeda M, Sims PJ, et al. Calcium-dependent phospholipid scrambling by TMEM16F. Nature 2010 ; 468 : 834-838.
PubMed
7) Chen VM, Hogg PJ. Encryption and decryption of tissue factor. J Thromb Haemost 2013 ; 11 (Suppl 1) : 277-284.
 
8) Lacroix R, Dubois C, Leroyer AS, et al. Revisited role of microparticles in arterial and venous thrombosis. J Thromb Haemost 2013 ; 11 (Suppl 1) : 24-35.
 
9) Lechtenberg BC, Freund SM, Huntington JA. An ensemble view of thrombin allostery. Biol Chem 2012 ; 393 : 889-898.
PubMed
10) Krishnaswamy S. The transition of prothrombin to thrombin. J Thromb Haemost 2013 ; 11 (Suppl 1) : 265-276.
 
11) Morrissey JH, Choi SH, Smith S. Polyphosphate : an ancient molecule that links platelets, coagulation, and inflammation. Blood 2012 ; 119 : 5972-5979.
PubMed
12) Schulz C, Engelmann B, Massberg S. Crossroads of coagulation and innate immunity : the case of deep vein thrombosis. J Thromb Haemost 2013 ; 11 (Suppl 1) : 233-241.
 
13) Maas C, Renne T. Regulatory mechanisms of the plasma contact system. Thromb Res 2012 ; 129 (Suppl 2) : S73-S76.
 
14) Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost 2012 ; 10 : 1478-1485.
PubMed
15) Kasahara K, Kaneda M, Miki T, et al. Clot retraction is mediated by factor XIII-dependent fibrin-α IIbβ 3-myosin axis in platelet sphingomyelin-rich membrane rafts. Blood 2013 ; 122 : 3340-3348.
 
16) Lam WA, Chaudhuri O, Crow A, et al. Mechanics and contraction dynamics of single platelets and implications for clot stiffening. Nat Mater 2011 ; 10 : 61-66.
PubMed
17) Kurniawan NA, Grimbergen J, Koopman J, et al. Factor XIII stiffens fibrin clots by causing fiber compaction. J Thromb Haemost 2014 ; 12 : 1687-1696.
PubMed
18) Aleman MM, Byrnes JR, Wang JG, et al. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest 2014 ; 124 : 3590-3600.
PubMed
19) Gosk-Bierska I, McBane RD, Wu Y, et al. Platelet factor XIII gene expression and embolic propensity in atrial fibrillation. Thromb Haemost 2011 ; 106 : 75-82.
PubMed
20) Fukudome K, Ye X, Tsuneyoshi N, et al. Activation mechanism of anticoagulant protein C in large blood vessels involving the endothelial cell protein C receptor. J Exp Med 1998 ; 187 : 1029-1035.
PubMed
21) Tollefsen DM. Heparin cofactor II modulates the response to vascular injury. Arterioscler Thromb Vasc Biol 2007 ; 27 : 454-460.
PubMed
22) Huntington JA. Thrombin inhibition by the serpins. J Thromb Haemost 2013 ; 11 (Suppl 1) : 254-264.
 
23) Hackeng TM, Sere KM, Tans G, et al. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 2006 ; 103 : 3106-3111.
PubMed
24) Law RH, Caradoc-Davies T, Cowieson N, et al. The X-ray crystal structure of full-length human plasminogen. Cell Rep 2012 ; 1 : 185-190.
PubMed
25) Bhattacharya S, Ploplis VA, Castellino FJ. Bacterial plasminogen receptors utilize host plasminogen system for effective invasion and dissemination. J Biomed Biotechnol 2012 ; 2012 : 482096.
PubMed
26) Miles LA, Lighvani S, Baik N, et al. New insights into the role of Plg-RKT in macrophage recruitment. Int Rev Cell Mol Biol 2014 ; 309 : 259-302.
PubMed
27) Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood 2013 ; 122 : 1873-1880.
PubMed
28) Antoniak S, Mackman N. Multiple roles of the coagulation protease cascade during virus infection. Blood 2014 ; 123 : 2605-2613.
PubMed
29) Woodruff RS, Sullenger B, Becker RC. The many faces of the contact pathway and their role in thrombosis. J Thromb Thrombolysis 2011 ; 32 : 9-20.
PubMed
30) Itakura A, Verbout NG, Phillips KG, et al. Activated factor XI inhibits chemotaxis of polymorphonuclear leukocytes. J Leukoc Biol 2011 ; 90 : 923-927.
PubMed
31) Von dem Borne PA, Bajzar L, Meijers JC, et al. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997 ; 99 : 2323-2327.
 
32) Bouwens EA, Stavenuiter F, Mosnier LO. Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. J Thromb Haemost 2013 ; 11 (Suppl 1) : 242-253.
 

III 凝固線溶系因子の名称と国際疾病分類

P.26 掲載の参考文献
1) Muszbek L, Ariens RA, Ichinose A ; ISTH SSC SUBCOMMITTEE ON FACTOR XIII. Factor XIII : recommended terms and abbreviations. J Thromb Haemost. 2007 ; 5 (1) : 181-183. Epub 2006 Aug 23.
 
2) 一瀬白帝編. 図説 血栓・止血・血管学-血栓症制圧のために-. 中外医学社, 2005.
 
3) Blomback M, Abildgaard U, van den Besselaar AM, et al. Nomenclature of quantities and units in thrombosis and haemostasis (recommendation 1993). A Collaborative project of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH/SSC) and the Commission/Committee on Quantities and Units (in Clinical Chemistry) of the International Union of Pure and Applied Chemistry-International Federation of Clinical Chemistry (IUPAC-IFCC/CQU (CC)). Thromb Haemost 1994 ; 71 : 375-394.
PubMed
4) 社団法人日本内科学会編. 内科学用語集 (第5版). 医学書院, 東京, 1998.
 
5) 日本医学会医学用語管理委員会編. 日本医学会医学用語辞典 英和 (第3版). 南山堂, 東京, 2007 (2013年6月より「医学会医学用語辞典Web版」が提供され, 2014年4月から一般公開されている).
 
6) 独立行政法人日本学術振興会. 文部科学省学術用語集医学編. 東京, 2003.
 
7) Uteg KH, Tausendfreund K. [Donor selection for the production of factor XIII preparations]. Folia Haematol Int Mag Klin Morphol Blutforsch 1985 ; 112 : 447-455.
PubMed
8) Nilsson IM. [Haemophilia--then and now]. Sydsven Medicinhist Sallsk Arsskr 1994 ; 31 : 33-52.
PubMed
9) Brackmann HH, Egbring R, Ferster A, et al. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma : a crossover randomised study. Thromb Haemost 1995 ; 74 : 622-625.
PubMed
10) Mutch NJ, Koikkalainen JS, Fraser SR, et al. Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis. J Thromb Haemost 2010 ; 8 : 2017-2024.
PubMed
11) Mannucci PM. Bleeding symptoms in heterozygous factor VIII deficiency. Haematologica 2010 ; 95 : e6 : Mannucci PM. Bleeding symptoms in heterozygous factor XIII [corrected] deficiency. Haematologica 2010 ; 95 : e6. Erratum in Haematologica 2010 ; 95 : 1800.
 
12) Biswas A, Ivaskevicius V, Thomas A, et al. Coagulation factor XIII deficiency. Diagnosis, prevalence and management of inherited and acquired forms. Hamostaseologie 2014 ; 34 : 160-166.
PubMed
13) Kurniawan NA, Grimbergen J, Koopman J, et al. Factor XIII stiffens fibrin clots by causing fiber compaction. J Thromb Haemost 2014 ; 12 : 1687-1696.
PubMed
14) Horowitz HI, Fujimoto MM. Acquired hemophilia due to a circulating anticoagulant. Report of two cases, with review of the literature. Am J Med 1962 ; 33 : 501-509.
PubMed
15) Frick PG. Hemophilia-like disease following pregnancy with transplacental transfer of an acquired circulating anticoagulant. Blood 1953 ; 8 : 598-608.
PubMed
16) Ichinose A ; Japanese Collaborative Research Group (JCRG) on AH13 Hemorrhagic Acquired Coagulopathies. Inhibitors of Factor XIII/13 in older patients. Semin Thromb Hemost 2014 ; 40 : 704-711.
 
17) Boggio LN, Green D. Acquired hemophilia. Rev Clin Exp Hematol 2001 ; 5 : 389-404.
PubMed
18) Brinkhous KM. A short history of hemophilia, with some comments on the word "Hemophilia." In : KM Brinkhous and HC Hemker, editors. Handbook of Hemophilia, Part 1, Amsterdam, New York : Excerpta Medica, American Elsevier Pub. Co. ; 1975, pp3-20.
 

IV 21世紀の研究と倫理 : 研究不正を防ぐために

P.32 掲載の参考文献
1) 香川知晶. 生命倫理の成立. 東京 : 勁草書房, 2000.
 
2) 文部科学省 科学技術・学術審議会 研究活動の不正行為に関する特別委員会. 研究活動の不正行為への対応のガイドラインについて-研究活動の不正行為に関する特別委員会報告書-. 2006. http://www.mext.go.jp/b_menu/shingi/gijyutu/gijyutu12/houkoku/_ics-Files/afieldfile/2013/05/07/1213547_001.pdf (2014/12/13閲覧)
 
3) 文部科学省科学技術政策研究所 第1調査研究グループ. 国立大学法人の財務分析. 2008. http://www.nistep.go.jp/achiev/ftx/jpn/mat150j/pdf/mat150j.pdf (2014/12/13閲覧)
 
4) 三宅康夫. 科学論文の捏造など研究における不正行為-その1 ショッキングな実情. Pharm Tech Japan 2008 ; 24 (1) : 67-75.
Medical*Online
5) 三宅康夫. 科学論文の捏造など研究における不正行為-その2 研究活動における不正行為の背景と不正研究行為の防止. Pharm Tech Japan 2008 ; 24 (2) : 63-71.
 
6) 山崎茂明. 科学の不正行為と出版倫理. 実験医学 2003 ; 21 (7) : 944-947.
Medical*Online
7) 文部科学省. 研究活動における不正行為への対応等に関するガイドライン . 2014. http://www.mext.go.jp/b_menu/houdou/26/08/_icsFiles/afieldfile/2014/08/26/1351568_02_1.pdf (2014/12/13閲覧)
 
8) 日本学術会議科学研究における健全性の向上に関する検討委員会. 提言 : 研究活動における不正の防止策と事後措置-科学の健全性向上ために-. 2013. http://www.scj.go.jp/ja/info/kohyo/pdf/kohyo-22-t131226.pdf (2014/12/13 閲覧)
 
9) 加藤浩. 研究活動における不正行為と法的規制. 薬学図書館 2014 ; 59 (3) : 196-203.
Medical*Online
10) 松澤孝明. わが国における研究不正 : 公開情報の基づくマクロ分析 (2). 情報管理 2013 ; 56 (4) : 222-235.
 
11) 山崎茂明. 薬学領域における研究者倫理 : 利益相反を考えるために. 薬学図書館 2009 ; 54 (3) : 168-174.
Medical*Online
12) 松澤孝明. わが国における研究不正 : 公開情報の基づくマクロ分析 (1). 情報管理 2013 ; 56 (3) : 156-165.
 

1部 血管

P.39 掲載の参考文献
1) Ross R. Atherosclerosis-an inflammatory disease. N Eng J Med 1999 ; 340 : 115-126.
 
2) Lee RT, Libby P. The unstable atheroma. Circulation 1997 ; 17 : 1859.
 
3) Butcher EC. Leukocyte-endothelial recognition : three (or more) steps to specificity and deiversity. Cell 1991 ; 67 : 1033.
 
4) Kodama T, Freeman M, Rohrer L, et al. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature 1990 ; 343 : 531-535.
PubMed
5) Suzuki H, Kurihara Y, Takeya M, et al. AS role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997 ; 386 : 292-296.
PubMed
6) Takahashi M. NLRP3 inflammasome as a novel player in myocardial infarction. Int Heart J 2014 ; 55 (2) : 101-105.
PubMed
7) Bostrom K, Watson KE, Horn S, et al. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Inverst 1993 ; 91 : 1800-1809.
 
8) Speer MY, Yang HY, Brabb T, et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 2009 ; 104 : 733-741.
PubMed
9) Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Eng J Med 1976 ; 295 : 369-377.
 
P.47 掲載の参考文献
1) Weiss L. The hematopoietic microenvironment of the bone marrow : an ultrastructural study of the stroma in rats. Anat Rec 1976 ; 186 (2) : 161-184.
PubMed
2) Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol 1977 ; 91 (3) : 335-344.
PubMed
3) Katayama Y, Frenette PS. Galactocerebrosides are required postnatally for stromal-dependent bone marrow lymphopoiesis. Immunity 2003 ; 18 (6) : 789-800.
PubMed
4) Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978 ; 4 : 7-25.
PubMed
5) Taichman RS, Emerson SG. Human osteoblasts support hematopoiesis through the production of granulocyte colony-stimulating factor. J Exp Med 1994 ; 179 (5) : 1677-1682.
PubMed
6) Zhang J, Niu C, Ye L,et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003 ; 425, 836-841.
PubMed
7) Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003 ; 425, 841-846.
PubMed
8) Xie T, Spradling AC. A niche maintaining germ line stem cells in the Drosophila ovary. Science 2000 ; 290 (5490) : 328-330.
PubMed
9) Song X, Zhu CH, Doan C, et al. Germline stem cells anchored by adherens junctions in the Drosophila ovary niches. Science 2002 ; 296 : 1855-1857.
PubMed
10) Visnjic D, Kalajzic Z, Rowe DW, et al. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood 2004 ; 103, 3258-3264.
PubMed
11) Arai F, Hirao A, Ohmura M, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004 ; 118 : 149-161.
PubMed
12) Kiel MJ, He S, Ashkenazi R, et al. Haematopoietic stem cells do not asymmetrically segregate chromosomes or retain BrdU. Nature 2007 ; 449 (7159) : 238-242.
PubMed
13) Kiel, MJ. Yilmaz OH, Iwashita T, et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005 ; 121 : 1109-1121.
PubMed
14) Kiel MJ, Radice GL, Morrison SJ. Lack of evidence that hematopoietic stem cells depend on N-cadherinmediated adhesion to osteoblasts for their maintenance. Cell Stem Cell 2007 ; 1 : 204-217.
 
15) Kiel MJ, Acar M, Radice GL, et al. Hematopoietic stem cells do not depend on N-cadherin to regulate their maintenance. Cell Stem Cell 2009 ; 4 : 170-179
PubMed
16) Greenbaum AM, Revollo LD, Woloszynek JR, et al. N-cadherin in osteolineage cells is not required for maintenance of hematopoietic stem cells. Blood 2012 ; 120 (2) : 295-302.
 
17) Bromberg O, Frisch BJ, Weber JM, et al. Osteoblastic N-cadherin is not required for microenvironmental support and regulation of hematopoietic stem and progenitor cells. Blood 2012 ; 120 (2) : 303-313.
 
18) Omatsu Y, Sugiyama T, Kohara H, et al. The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity 2010 ; 33 (3) : 387-399.
PubMed
19) Li JY, Adams J, Calvi LM, et al. PTH expands shortterm murine hemopoietic stem cells through T cells. Blood 2012 ; 120 (22) : 4352-4362.
PubMed
20) Miller CL, Rebel VI, Lemieux ME, et al. Studies of W mutant mice provide evidence for alternate mechanisms capable of activating hematopoietic stem cells. Exp Hematol 1996 ; 24 (2) : 185-194.
PubMed
21) Kimura Y, Ding B, Imai N, et al. c-Kit-mediated functional positioning of stem cells to their niches is essential for maintenance and regeneration of adult hematopoiesis. PLoS One 2011 ; 6 (10) : e26918.
PubMed
22) Ding L, Saunders TL, Enikolopov G, et al. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 2012 ; 481 (7382) : 457-462.
PubMed
23) Oguro H, Ding L, Morrison SJ. SLAM Family Markers Resolve Functionally Distinct Subpopulations of Hematopoietic Stem Cells and Multipotent Progenitors. Cell Stem Cell 2013 ; 13 (1) : 102-116.
PubMed
24) Kimura S, Roberts AW, Metcalf D. Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci U S A 1998 ; 95 (3) : 1195-1200.
PubMed
25) Buza-Vidas N, Antonchuk J, Qian H, et al. Cytokines regulate postnatal hematopoietic stem cell expansion : opposing roles of thrombopoietin and LNK. Genes 2006 ; 20 (15) : 2018-2023.
PubMed
26) Sugiyama T, Kohara H, Noda M, et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006 ; 25 : 977-988.
PubMed
27) Greenbaum A, Hsu YM, Day RB, et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature 2013 ; 495 : 227-230.
PubMed
28) Ding L, Morrison SJ. Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature 2013 ; 495 : 231-235.
PubMed
29) Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996 ; 382 : 635-638.
PubMed
30) Ara T, Tokoyoda K, Sugiyama T, et al. Long-term hematopoietic stem cells require stromal cell-derived factor-1 for colonizing bone marrow during ontogeny. Immunity 2003 ; 19 : 257-267.
 
31) Tokoyoda K, Egawa T, Sugiyama T, et al. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 2004 ; 20 (6) : 707-718.
PubMed
32) Zhou BO, Yue R, Murphy MM, et al. Leptin-Receptor-Expressing Mesenchymal Stromal Cells Represent the Main Source of Bone Formed by Adult Bone Marrow. Cell Stem Cell 2014 ; 15 : 154-168.
PubMed
33) Day K, Shefer G, Richardson JB, et al. Nestin-GFP reporter expression defines the quiescent state of skeletal muscle satellite cells. Dev Biol 2007 ; 304 : 246-259.
PubMed
34) Mendez-Ferrer S, Michurina TV, Ferraro F,. et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010 ; 466 : 829-834.
 
35) Kunisaki Y, Bruns I, Scheiermann C, et al. Arteriolar niches maintain haematopoietic stem cell quiescence. Nature 2013 ; 502 (7473) : 637-643.
PubMed
36) Yamazaki S, Ema H, Karlsson G, et al. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 2011 ; 147 (5) : 1146-1158.
PubMed
37) Omatsu Y, Seike M, Sugiyama T, et al. Foxc1 is a critical regulator of haematopoietic stem/progenitor cell niche formation. Nature2014 ; 508 (7497) : 536-540.
 
38) Nishimura DY, Swiderski RE, Alward WL, et al. The forkhead transcription factor gene FKHL7 is responsible for glaucoma phenotypes which map to 6p25. Nat Genet 1998 ; 19 (2) : 140-147.
 
39) Aldinger KA, Lehmann OJ, Hudgins L, et al. FOXC1 is required for normal cerebellar development and is a major contributor to chromosome 6p25.3 Dandy-Walker malformation. Nat Genet 2009 ; 41 (9) : 1037-1042.
 
40) Kume T, Deng KY, Winfrey V,et al. The forkhead/winged helix gene Mf1 is disrupted in the pleiotropic mouse mutation congenital hydrocephalus. Cell 1998 ; 12 ; 93 (6) : 985-996.
 
41) Maes C, Kobayashi T, Selig MK, et al. Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. Dev Cell 2010 ; 19 : 329-344.
PubMed
42) Morikawa S, Mabuchi Y, Kubota Y, et al. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J Exp Med 2009 ; 206 : 2483-2496.
PubMed
43) Nagasawa T, Omatsu Y, Sugiyama T. Control of hematopoietic stem cells by the bone marrow stromal niche : the role of reticular cells. Trends Immunol 2011 ; 32 (7) : 315-320.
PubMed
P.55 掲載の参考文献
1) Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005 ; 97 (6) : 512-523.
PubMed
2) Asahara T, Kawamoto A, Masuda H. Concise review : Circulating endothelial progenitor cells for vascular medicine. Stem Cells 2011 ; 29 (11) : 1650-1655.
PubMed
3) Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000 ; 6 (4) : 389-395.
PubMed
4) Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature 2005 ; 438 (7070) : 937-945.
PubMed
5) Duarte A, Hirashima M, Benedito R, et al. Dosagesensitive requirement for mouse Dll4 in artery development. Genes Dev 2004 ; 18 (20) : 2474-2478.
PubMed
6) Francois M, Caprini A, Hosking B, et al. Sox18 induces development of the lymphatic vasculature in mice. Nature 2008 ; 456 (7222) : 643-647.
PubMed
7) Fritz-Six KL, Dunworth WP, Li M, et al. Adrenomedullin signaling is necessary for murine lymphatic vascular development. J Clin Invest 2008 ; 118 (1) : 40-50.
PubMed
8) Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002 ; 3 (3) : 411-423.
PubMed
9) Herbert SP, Stainier DY. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol 2011 ; 12 (9) : 551-564.
PubMed
10) Kajiya K, Hirakawa S, Ma B, et al. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 2005 ; 24 (16) : 2885-2895.
PubMed
11) Lin Y, Weisdorf DJ, Solovey A, et al. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000 ; 105 (1) : 71-77.
 
12) Naito H, Kidoya H, Sakimoto S, et al. Identification and characterization of a resident vascular stem/progenitor cell population in preexisting blood vessels. EMBO J 2012 ; 31 (4) : 842-855.
PubMed
13) Norrmen C, Tammela T, Petrova TV, et al. Biological basis of therapeutic lymphangiogenesis. Circulation 2011 ; 123 (12) : 1335-1351.
PubMed
14) Oliver G, Srinivasan RS. Endothelial cell plasticity : how to become and remain a lymphatic endothelial cell. Development 2010 ; 137 (3) : 363-372.
PubMed
15) Phng LK, Gerhardt H. Angiogenesis : a team effort coordinated by notch. Dev Cell 2009 ; 16 (2) : 196-208.
PubMed
16) Risau W. Mechanisms of angiogenesis. Nature 1997 ; 386 (6626) : 671-674.
PubMed
17) Sabine A, Agalarov Y, Maby-El Hajjami H, et al. Mechanotransduction, PROX1, and FOXC2 cooperate to control connexin37 and calcineurin during lymphatic-valve formation. Dev Cell 2012 ; 22 (2) : 430-445.
PubMed
18) Suzuki-Inoue K, Inoue O, Ding G, et al. Essential in vivo roles of the C-type lectin receptor CLEC-2 : embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem 2010 ; 285 (32) : 24494-24507.
 
19) Tammela T, Alitalo K. Lymphangiogenesis : Molecular mechanisms and future promise. Cell 2010 ; 140 (4) : 460-476.
PubMed
20) Yang Y, Oliver G. Development of the mammalian lymphatic vasculature. J Clin Invest 2014 ; 124 (3) : 888-897.
PubMed
21) You LR, Lin FJ, Lee CT, et al. Suppression of Notch signalling by the COUP-TFII transcription factor regulates vein identity. Nature 2005 ; 435 (7038) : 98-104.
PubMed
P.63 掲載の参考文献
1) Quaegebeur A, Lange C, Carmeliet P. The neurovascular link in health and disease : molecular mechanisms and therapeutic implications. Neuron 2011 ; 71 (3) : 406-424.
PubMed
2) Va sudevan A, Long JE, Crandall JE, et al. Compartment-specific transcription factors orchestrate angiogenesis gradients in the embryonic brain. Nature Neuroscience 2008 ; 11 (4) : 429-439.
 
3) Kurz H, Gartner T, Eggli PS, et al. First blood vessels in the avian neural tube are formed by a combination of dorsal angioblast immigration and ventral sprouting of endothelial cells. Dev Biol 1996 ; 173 (1) : 133-147.
PubMed
4) Hogan KA, Ambler CA, Chapman DL, et al. The neural tube patterns vessels developmentally using the VEGF signaling pathway. Development 2004 ; 131 (7) : 1503-1513.
PubMed
5) Ruhrberg C, Gerhardt H, Golding M, et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 2002 ; 16 (20) : 2684-2698.
PubMed
6) Gerhardt H, Ruhrberg C, Abramsson A, et al. Neuropilin-1 is required for endothelial tip cell guidance in the developing central nervous system. Developmental Dynamics 2004 ; 231 (3) : 503-539.
PubMed
7) Ruhrberg C, Bautch VL. Neurovascular development and links to disease. Cellular and Molecular Life Sciences 2013 ; 70 (10) : 1675-1684.
PubMed
8) James JM, Gewolb C, Bautch VL. Neurovascular development uses VEGF-A signaling to regulate blood vessel ingression into the neural tube. Development 2009 ; 136 (5) : 833-841.
PubMed
9) Kurz H. Cell lineages and early patterns of embryonic CNS vascularization. Cell Adh Migr 2009 ; 3 (2) : 205-210.
PubMed
10) Takahashi T, Takase Y, Yoshino T, Saito D, et al. Angiogenesis in the developing spinal cord : blood vessel exclusion from neural progenitor region is mediated by VEGF and its antagonists. PloS one 2015 ; 10 (1) : e0116119.
PubMed
11) Haigh JJ, Morelli PI, Gerhardt H, et al. Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Developmental Biology 2003 ; 262 (2) : 225-241.
PubMed
12) Ng YS, Rohan R, Sunday ME, et al. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn 2001 ; 220 (2) : 112-121.
PubMed
13) Armulik A, Genove G, Betsholtz C. Pericytes : developmental, physiological, and pathological perspectives, problems, and promises. Developmental cell 2011 ; 21 (2) : 193-215.
PubMed
14) Lindahl P, Johansson BR, Leveen P, et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997 ; 277 (5323) : 242-245.
PubMed
15) Ma S, Kwon HJ, Johng H, Zang K, et al. Radial Glial Neural Progenitors Regulate Nascent Brain Vascular Network Stabilization Via Inhibition of Wnt Signaling. PLoS Biology 2013 ; 11 (1) : e1001469.
 
16) James JM, Mukouyama YS. Neuronal action on the developing blood vessel pattern. Semin Cell Dev Biol 2011 ; 22 (9) : 1019-1027.
PubMed
17) Stenman JM, Rajagopal J, Carroll TJ, et al. Canonical Wnt Signaling Regulates Organ-Specific Assembly and Differentiation of CNS Vasculature. Science 2008 ; 322 (5905) : 1247-1250.
PubMed
18) Mukouyama YS, Shin D, Britsch S, et al. Sensory nerves determine the pattern of arterial differentiation and blood vessel branching in the skin. Cell 2002 ; 109 (6) : 693-705.
PubMed
19) Li W, Kohara H, Uchida Y, et al. Peripheral nervederived CXCL12 and VEGF-A regulate the patterning of arterial vessel branching in developing limb skin. Developmental cell 2013 ; 24 (4) : 359-371.
PubMed
20) Nam J, Onitsuka I, Hatch J, et al. Coronary veins determine the pattern of sympathetic innervation in the developing heart. Development 2013 ; 140 (7) : 1475-1485.
PubMed
21) Honma Y, Araki T, Gianino S, et al. Artemin is a vascular-derived neurotropic factor for developing sympathetic neurons. Neuron 2002 ; 35 (2) : 267282.
 
22) Makita T, Sucov HM, Gariepy CE, et al. Endothelins are vascular-derived axonal guidance cues for developing sympathetic neurons. Nature 2008 ; 452 (7188) : 759-763.
PubMed
23) Saito D, Takase Y, Murai H, et al. The Dorsal Aorta Initiates a Molecular Cascade That Instructs Sympatho-Adrenal Specification. Science 2012 ; 336 (6088) : 1578-1581.
PubMed
P.71 掲載の参考文献
1) Kamiya A, Bukhari R, and Togawa T. Adaptive regulation of wall shear stress optimizing vascular tree function. Bull Math Biol 1984 ; 46 : 127-137.
PubMed
2) Dobrin PB. Mechanical properties of arteries. In : Caro CG, Pedley TJ, Schroter RC, Seed WA, eds. The mechanics of the circulation. New York : Oxford University Press 1978 : 397.
 
3) Masuda H, Kawamura K, Tohda K, et al. Increase in endothelial cell density before artery enlargement in flow-loaded canine carotid artery. Arteriosclerosis 1989 ; 9 : 812-823.
PubMed
4) Ando J, Nomura H, Kamiya A. The effect of fluid shear stress on the migration and proliferation of cultured endothelial cells. Microvasc Res 1987 ; 33 : 62-70.
PubMed
5) Kaiser D, Freyberg MA, Friedl P. Lack of hemodynamic forces triggers apoptosis in vascular endothelial cells. Biochem Biophys Res Commun 1997 ; 231 : 586-590.
PubMed
6) Korenaga R, Ando J, Tsuboi H, et al. Laminar flow stimulates ATP- and shear stress-dependent nitric oxide production in cultured bovine endothelial cells. Biochem Biophys Res Commun 1994 ; 198 : 213-219.
PubMed
7) Takada Y, Shinkai F, Kondo S, et al. Fluid shear stress increases the expression of thrombomodulin by cultured human endothelial cells. Biochem Biophys Res Commun 1994 ; 205 : 1345-1352.
PubMed
8) Kosaki K, Ando J, Korenaga R, et al. Fluid shear stress increases the production of granulocyte-macrophage colony-stimulating factor by endothelial cells via mRNA stabilization. Circ Res 1998 ; 82 : 794-802.
PubMed
9) Ando J, Tsuboi H, Korenaga R, et al. Shear stress inhibits adhesion of cultured mouse endothelial cells to lymphocytes by downregulating VCAM-1 expression. Am J Physiol 1994 ; 267 : C679-C687.
PubMed
10) Tsuboi H, Ando J, Korenaga R, et al. Flow stimulates ICAM-1 expression time and shear stress dependently in cultured human endothelial cells. Biochem Biophys Res Commun 1995 ; 206 : 988-996.
PubMed
11) Laurindo FR, Pedro MdeA, Barbeiro HV, et al. Vascular free radical release. Ex vivo and in vivo evidence for a flow-dependent endothelial mechanism. Circ Res 1994 ; 74 : 700-709.
PubMed
12) Ohura N, Yamamoto K, Ichioka S, et al. Global analysis of shear stress-responsive genes in vascular endothelial cells. J Atheroscler Thromb 2003 ; 10 : 304-313.
PubMed
13) Ando J, Korenaga R, Kamiya A. Flow-induced Endothelial Gene Regulation. In : Mechanical Forces and the Endothelium, edited by Lelkes, P.I. Singapore : harwood academic publishers, 1999 : 111-126.
 
14) Boon RA, Hergenreider E, Dimmeler S. Atheroprotective mechanisms of shear stress-regulated microRNAs. Thromb Haemost 2012 ; 108 : 616-620.
PubMed
15) Sokabe T, Yamamoto K, Ohura N, et al. Differential regulation of urokinase-type plasminogen activator expression by fluid shear stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 2004 ; 287 : H2027-H2034.
PubMed
16) Sumpio BE, Banes AJ, Buckley M, et al. Alterations in aortic endothelial cell morphology and cytoskeletal protein synthesis during cyclic tensional deformation. J Vasc Surg 1988 ; 7 : 130-138.
PubMed
17) Ando J, Yamamoto K. Flow detection and calcium signaling in vascular endothelial cells. Cardiovasc Res 2013 ; 99 : 260-268.
PubMed
18) Yamamoto K, Ando J. Endothelial cell and model membranes respond to shear stress by rapidly decreasing the order of their lipid phases. J Cell Sci 2013 ; 126 : 1227-1234.
PubMed
19) Yamamoto K, Furuya K, Nakamura M, et al. Visualization of flow-induced ATP release and triggering of Ca2+ waves at caveolae in vascular endothelial cells. J Cell Sci 2011 ; 124 : 3477-3483.
PubMed
20) O'Neil, R.G. and Heller, S. The mechanosensitive nature of TRPV channels. Pflugers Arch 2005 ; 451 : 193-203.
PubMed
21) Naruse K, Sokabe M. Involvement of stretch-activated ion channels in Ca2+ mobilization to mechanical stretch in endothelial cells. Am J Physiol 1993 ; 264 : C1037-C1044.
PubMed
22) Kakisis JD, Liapis CD, Sumpio BE. Effects of cyclic strain on vascular cells. Endothelium 2004 ; 11 : 17-28.
PubMed
23) Yamamoto K, Sokabe T, Matsumoto T, et al. Impaired flow-dependent control of vascular tone and remodeling in P2X4-deficient mice. Nat Med 2006 ; 12 : 133-137.
PubMed
24) Hove JR, Koster RW, Forouhar AS, et al. Intracardiac fluid forces are an essential epigenetic factor for embryonic cardiogenesis. Nature 2003 ; 421 : 172-177.
PubMed
25) Masumura T, Yamamoto K, Shimizu N, et al. Shear stress increases expression of the arterial endothelial marker ephrinB2 in murine ES cells via the VEGFNotch signaling pathways. Arterioscler Thromb Vasc Biol 2009 ; 29 : 2125-2131.
PubMed
26) Nonaka S, Shiratori H, Saijoh Y, et al. Determination of left-right patterning of the mouse embryo by artificial nodal flow. Nature 2002 ; 418 : 96-99.
PubMed
27) Hahn C, Schwartz MA. Mechanotransduction in vascular physiology and atherogenesis. Nat Rev Mol Cell Biol 2009 ; 10 : 53-62.
PubMed
28) Aoki T, Nishimura M, Matsuoka T, et al. PGE2-EP2 signalling in endothelium is activated by haemodynamic stress and induces cerebral aneurysm through an amplifying loop via NF-kappaB. Br J Pharmacol 2011 ; 163 : 1237-1249.
PubMed
29) Ohkubo T, Fukazawa R, Ikegami E, et al. Reduced shear stress and disturbed flow may lead to coronary aneurysm and thrombus formations. Pediatr Int 2007 ; 49 : 1-7.
PubMed
30) Niebauer J, Cooke JP. Cardiovascular effects of exercise : role of endothelial shear stress. J Am Coll Cardiol 1996 ; 28 : 1652-1660.
PubMed
P.81 掲載の参考文献
1) Vu TK, Hung DT, Wheaton VI, et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991 ; 64 (6) : 1057-1068.
PubMed
2) Jacques S, Kuliopulos A. Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage. Biochem J 2003 ; 376 : 733-740.
 
3) Tamura N, Kitajima I, Kawamura Y, et al. Important regulatory role of activated platelet-derived procoagulant activity in the propagation of thrombi formed under arterial blood flow conditions. Circ J 2009 ; 73 (3) : 540-548.
PubMed
4) Kahn ML, Nakanishi-Matsui M, Shapiro MJ, et al. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999 ; 103 (6) : 879-887.
PubMed
5) Soh UJK, Dores MR, Chen B, et al. Signal transduction by protease ‐ activated receptors. Br J Pharmacol 2010 ; 160 (2) : 191-203.
 
6) Leger AJ, Jacques SL, Badar J, et al. Blocking the protease-activated receptor 1-4 heterodimer in plateletmediated thrombosis. Circulation 2006 ; 113 (9) : 1244-1254.
PubMed
7) Covic L, Singh C, Smith H, et al. Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome. Thromb Haemost 2002 ; 87 (4) : 722-727.
PubMed
8) Leonardi S, Tricoci P, Mahaffey KW. Promises of PAR-1 inhibition in acute coronary syndrome. Curr Cardiol Rep 2012 ; 14 (1) : 32-39.
PubMed
9) Tricoci P, Huang Z, Held C, et al ; TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Eng J Med 2012 ; 366 (1) : 20-33.
 
10) Leonardi S, Tricoci P, Mahaffey KW. Promises of PAR-1 inhibition in acute coronary syndrome. Curr Cardiol Rep 2012 ; 14 (1) : 32-39.
PubMed
11) Morrow DA, Braunwald E, Bonaca MP, et al ; TRA2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events.N Eng J Med 2012 ; 366 (15) : 1404-1413.
 
12) 駒井太一. トロンビン受容体阻害薬. 内科 2012 ; 110 (1) : 74-78.
 
P.88 掲載の参考文献
1) Hellstrom M, Phng LK, Hofmann JJ, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007 ; 445 : 776-780.
PubMed
2) Goveia J, Zecchin A, Rodriguez FM, et al. Endothelial cell differentiation by SOX17 : promoting the tip cell or stalking its neighbor instead? Circ Res 2014 ; 115 : 205-207.
PubMed
3) Phng LK, Gerhardt H. Angiogenesis : a team effort coordinated by notch. Dev Cell 2009 ; 16 : 196-208.
PubMed
4) Naito H, Kidoya H, Sakimoto S, et al. Identification and characterization of a resident vascular stem/progenitor cell population in preexisting blood vessels. EMBO J 2012 ; 31 : 842-855.
PubMed
5) Krueger J, Liu D, Sholz K, et al. Flt1 acts as a negative regulator of tip cell formation and branching morphogenesis in the zebrafish embryo. Development 2011 ; 138 : 2111-2120.
 
6) Fantin A, Vieira JM, Plein A, et al. NRP1 acts cell autonomously in endothelium to promote tip cell function during sprouting angiogenesis. Blood 2013 ; 121 : 2352-2362.
 
7) Mazzone M, Dettori D, Leite de Oliveira R, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009 ; 136 : 839-851.
 
8) Augustin HG, Koh GY, Thurston G, et al. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009 ; 10 : 165-177.
PubMed
9) Jeansson M, Gawlik A, Anderson G, et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest 2011 ; 121 : 2278-2289.
PubMed
10) Gavard J, Patel V, Gutkind JS. Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev Cell 2008 ; 14 : 25-36.
PubMed
11) Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997 ; 277 : 55-61.
PubMed
12) Muramatsu F, Kidoya H, Naito H, et al. microRNA-125b inhibits tube formation of blood vessels through translational suppression of VE-cadherin. Oncogene 2013 ; 32 : 414-421.
PubMed
13) Takakura N. Role of intimate interactions between endothelial cells and the surrounding accessory cells in the maturation of blood vessels. J Thromb Haemost 2011 ; 9 : 144-150.
PubMed
14) Abtahian F, Guerriero A, Sebzda E, et al. Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science 2003 ; 299 : 247-251.
PubMed
15) Takakura N, Huang XL, Naruse T, et al. Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. Immunity 1998 ; 9 : 677-686.
PubMed
16) Takakura N, Watanabe T, Suenobu S, et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell 2000 ; 102 : 199-209.
PubMed
17) Fukuhara S, Sako K, Minami T, et al. Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat Cell Biol 2008 ; 10 : 513-526.
PubMed
18) Yamada Y, Takakura N. Physiological pathway of differentiation of hematopoietic stem cell population into mural cells. J Exp Med 2006 ; 203 : 1055-1065.
 
19) Kidoya H, Ueno M, Yamada Y, et al. Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J 2008 ; 27 : 522-534.
PubMed
20) Kidoya H, Naito H, Takakura N. Apelin induces enlarged and nonleaky blood vessels for functional recovery from ischemia. Blood 2010 ; 115 : 3166-3174.
PubMed
21) Hida K, Hida Y, Amin DN, et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004 ; 64 : 8249-8255.
PubMed
22) Ricci-Vitiani L, Pallini R, Biffoni M, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010 ; 468 : 824-828.
PubMed
23) Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010 ; 468 : 829-833.
PubMed
24) Jain RK. Normalization of tumor vasculature : An emerging concept in antiangiogenic therapy. Science 2005 ; 307 : 58-62.
PubMed
25) Kidoya H, Kunii N, Naito H, et al. The apelin/APJ system induces maturation of the tumor vasculature and improves the efficiency of immune therapy. Oncogene 2012 ; 31 : 3254-3264.
PubMed
P.95 掲載の参考文献
1) Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995 ; 92 : 1355-1374.
 
2) Manabe I, Nagai R. Regulation of smooth muscle phenotype. Curr Atheroscler Rep 2003 ; 5 : 214-222.
PubMed
3) Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012 ; 32 : 2045-2051.
PubMed
4) Nakashima Y, Fujii H, Sumiyoshi S, et al. Early human atherosclerosis : accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol 2007 ; 27 : 1159-1165.
PubMed
5) Kisanuki A, Asada Y, Sato Y, et al. Coronary atherosclerosis in youths in Kyushu Island, Japan : histological findings and stenosis. J Atheroscler Thromb 2000 ; 6 : 55-59.
PubMed
6) Nakashima Y, Chen YX, Kinukawa N, et al. Distributions of diffuse intimal thickening in human arteries : preferential expression in atherosclerosis-prone arteries from an early age. Virchows Arch 2002 ; 441 : 279-288.
PubMed
7) Tanaka K, Masuda J, Imamura T, et al. A nation-wide study of atherosclerosis in infants, children and young adults in Japan. Atherosclerosis 1988 ; 72 : 143-156.
 
8) Imakita M, Yutani C, Strong JP, et al. Second nationwide study of atherosclerosis in infants, children and young adults in Japan. Atherosclerosis 2001 ; 155 : 487-497.
 
9) Sawabe M, Arai T, Kasahara I, et al. Sustained progression and loss of the gender-related difference in atherosclerosis in the very old : a pathological study of 1074 consecutive autopsy cases. Atherosclerosis 2006 ; 186 : 374-379.
 
10) Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 2003 ; 41 : 15S-22S.
PubMed
11) Finn AV, Nakano M, Narula J, et al. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010 ; 30 : 1282-1292.
PubMed
12) Hatakeyama K, Asada Y, Marutsuka K, et al. Localization and activity of tissue factor in human aortic atherosclerotic lesions. Atherosclerosis 1997 ; 133 : 213-219.
PubMed
13) Sato Y, Hatakeyama K, Yamashita A, et al. Proportion of fibrin and platelets differs in thrombi on ruptured and eroded coronary atherosclerotic plaques in humans. Heart 2005 ; 91 : 526-530.
PubMed
14) Yamashita A, Asada Y. Pathology and pathophysiology of atherothrombosis : Virchow' s triad revisited. In : Gaxiola E, ed. Traditional and Novel Risk Factors in Atherothrombosis. Rijeka : InTech, 2012 : 1-20.
 
P.100 掲載の参考文献
1) Hunt KJ, Resendez RG, Williams K, et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to allcause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004 ; 110 (10) : 1251-1257.
 
2) Kannel WB, Wolf PA, Castelli WP, et al. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987 ; 4 ; 258 (9) : 1183-1186.
 
3) Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001 ; 24 (4) : 683-689.
PubMed
4) Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002 ; 288 (21) : 2709-2716.
PubMed
5) Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010 ; 56 (14) : 1113-1132.
PubMed
6) Takeuchi H, Saitoh S, Takagi S, et al. Metabolic syndrome and cardiac disease in Japanese men : applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program-Adult Treatment Panel III to Japanese men-the Tanno and Sobetsu Study. Hypertens Res 2005 ; 28 (3) : 203-208.
PubMed
7) Nakamura T, Yamamoto T, Okamura T, et al. Combined cardiovascular risk factors and outcome : NIPPON DATA80, 1980-1994. Circ J 2006 ; 70 (8) : 960-964.
 
8) Ageno W, Prandoni P, Romualdi E, et al. The metabolic syndrome and the risk of venous thrombosis : a case-control study. J Thromb Haemost 2006 ; 4 (9) : 1914-1918.
PubMed
9) Mitchell JA, Ali F, Bailey L, et al. Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp Physiol 2008 ; 93 : 141-147.
PubMed
10) Lowenstein CJ. Nitric oxide regulation of protein trafficking in the cardiovascular system. Cardiovasc Res 2007 ; 75 : 240-246.
PubMed
11) Mizumoto N, Kumamoto T, Robson SC, et al. CD39 is the dominant Langerhans cell-associated ecto-NTPDase : modulatory roles in inflammation and immune responsiveness. Nat Med 2002 ; 8 : 358-365.
PubMed
12) Mackman N, Taubman MB. Does tissue factor expression by vascular smooth muscle cells provide a link between C-reactive protein and cardiovascular disease? Arterioscler Thromb Vasc Biol 2008 ; 28 : 601-603.
PubMed
13) Esmon CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med 2002 ; 196 : 561-564.
 
14) Chen VM, Hogg PJ. Allosteric disulfide bonds in thrombosis and thrombolysis. J Thromb Haemost 2006 ; 4 : 2533-2541.
PubMed
15) Nakajima T, Kitajima I, Shin H, et al. Involvement of NF-kappa B activation in thrombin-induced human vascular smooth muscle cell proliferation. Biochem Biophys Res Commun 1994 ; 204 : 950-958.
PubMed
16) Kawahara K, Watanabe S, Ohshima T, et al. Hypernuclear acetylation in atherosclerotic lesions and activated vascular smooth muscle cells. Biochem Biophys Res Commun 1999 ; 266 : 417-424.
PubMed
17) Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006 ; 444 (7121) : 860-867.
PubMed
18) Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome : links, causes, and consequences. Arterioscler Thromb Vasc Biol. 2006 ; 26 (10) : 2200-2207.
PubMed
19) Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat : possible contributor to vascular disease in obesity. Nat Med 1996 ; 2 (7) : 800-803.
PubMed
20) Ross R. Atherosclerosis ? an inflammatory disease. N Engl J Med 1999 ; 14 ; 340 (2) : 115-126.
 
21) Libby P. Inflammation in atherosclerosis. Nature 2002 ; 420 (6917) : 868-874.
PubMed
22) Hsueh WA, Lyon CJ, Quinones MJ. Insulin resistance and the endothelium. New Eng J Med 2004 ; 117 (2) : 109-117.
 
23) Goldin A, Beckman JA, Schmidt AM, et al. Advanced glycation end products : sparking the development of diabetic vascular injury. Circulation 2006 ; 114 (6) : 597-605.
PubMed
24) Marui N, Offermann MK, Swerlick R, et al : Vascular cell adhesion molecule-1 ( VCAM-1) gene transcription and expression are regulated through an antioxidantsensitive mechanism in human vascular endothelial cells. J Clin Invest 1993 ; 92 : 1866-1874.
PubMed
25) 6) DeKeulenaer GW, Ushio-Fukai M, Yin Q, et al. Convergence of redox-sensitive and mitogen-activated protein kinase signaling pathways in tumor necrosis factor-α-mediated monocyte chemoattractant protein-1 induction in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000 ; 20 : 385-391.
 
26) Li DY, Zhang YC, Philips MI, et al. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res 1999 ; 84 : 1043-1049.
PubMed
27) Liao F, Andalibi A, Qiao JH, et al. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest 1994 ; 94 : 877-884.
PubMed
28) Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells : A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995 ; 95 : 995-1001.
PubMed
29) Ito TK, Yokoyama M, Yoshida Y, et al. A crucial role for CDC42 in senescence-associated inflammation and atherosclerosis. PLoS One 2014 ; 9 (7) : e102186.
PubMed
30) Minamino T, Miyauchi H, Yoshida T, et al. Endothelial cell senescence in human atherosclerosis : role of telomere in endothelial dysfunction. Circulation 2002 ; 105 (13) : 1541-1544.
PubMed
31) Minamino T, Komuro I. Vascular cell senescence : contribution to atherosclerosis. Circ Res 2007 ; 100 (1) : 15-26.
PubMed
32) Miyauchi H, Minamino T, Tateno K, et al. Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway. EMBO J 2004 ; 23 (1) : 212-220.
 
33) Kunieda T, Minamino T, Nishi J, et al. Angiotensin II induces premature senescence of vascular smooth muscle cells and accelerates the development of atherosclerosis via a p21-dependent pathway. Circulation 2006 ; 114 (9) : 953-960.
 
34) Yokoyama M, Okada S, Nakagomi A, et al. Inhibition of endothelial p53 improves metabolic abnormalities related to dietary obesity. Cell Rep 2014 ; 7 (5) : 1691-1703.
PubMed
35) Minamino T, Orimo M, Shimizu I, et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat Med 2009 ; 15 : 1082-1087.
 
36) Shimizu I, Yoshida Y, Katsuno T, et al. p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. Cell Metab 2012 ; 15 (1) : 51-64.
PubMed
37) Shimizu I, Minamino T, Toko H, et al. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest 2010 ; 120 : 1506-1514.
PubMed
P.109 掲載の参考文献
1) 小林隆夫編. 静脈血栓塞栓症ガイドブック改訂2版. 東京 : 中外医学社, 2010.
 
2) 小林隆夫. 静脈血栓塞栓症の予防対策. 日本臨牀 2014 ; 72 (7) : 1303-1308.
Medical*Online
3) Sakuma M, Nakamura M, Yamada N, et al. Venous thromboembolism : deep vein thrombosis with pulmonary embolism, deep vein thrombosis alone, and pulmonary embolism alone. Circ J 2009 ; 73 (2) : 305-309.
PubMed
4) 小嶋哲人, 太田覚史. 肺血栓塞栓症・深部静脈血栓症全国調査研究. In : 厚生労働省科学研究費補助金 難治性疾患克服研究事業「血液凝固異常症に関する調査研究」平成25年度総括・分担研究報告書. 2014 : 163-169.
 
5) 黒岩政之, 入田和男, 讃岐美智義, 他 . 2009-2011年周術期肺塞栓症調査結果から見た本邦における周術期肺血栓塞栓症の特徴. 麻酔 2013 ; 62 : 629-638.
Medical*Online
6) Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001 ; 119 (1 Suppl) : 132S-175S.
 
7) 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン作成委員会. 肺血栓塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン. 東京 : メディカル フロント インターナショナル リミテッド, 2004.
 
8) 日本循環器学会合同研究班. 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告) : 肺血栓塞栓症および深部静脈血栓症の診断・治療・予防に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_andoh_h.pdf
 
9) JCS Joint Working Group. Guidelines for the Diagnosis, Treatment and Prevention of Pulmonary Thromboembolism and Deep Vein Throm-bosis (JCS2009) Digest Version-. Circ J 2011 ; 75 (5) : 1258-1281.
 
10) National Institute for Health and Care Excellence. CG92 Venous thromboembolism - reducing the risk : understanding NICE guidance, 2010. http://www.nice.org.uk/guidance/CG92
 
11) 小林隆夫. 周産期における肺血栓塞栓症対策. 静岡県母性衛生学会学術雑誌 2011 ; 1 (1) : 3-10.
 
12) 小林隆夫. 研修コーナー. 妊産婦死亡報告からみた母体安全への提言 4) 肺血栓塞栓症. 日本産科婦人科学会誌 2012 ; 64 (9) 別冊 : N418-N424.
 
13) 公益社団法人日本産科婦人科学会, 公益社団法人日本産婦人科医会, 日本産婦人科・新生児血液学会, 他. ヘパリン在宅自己注射療法の適応と指針. 2011. http://www.jsognh.jp/common/files/society/demanding_paper_07.pdf
 
14) 小林隆夫. ガイドライン ここがポイント! ヘパリン在宅自己注射療法の適応と指針. Thrombosis Medicine 2013 ; 3 (4) : 71-75.
 
P.117 掲載の参考文献
1) Iwai T, Inoue Y, Umeda M, et al. Oral bacteria in the occluded arteries of patients with Buerger disease. J Vasc Surg 2005 ; 42 : 107-115.
PubMed
2) 重松宏, 大城秀巳.【血栓症と抗血栓薬】血栓症の臨床疫学と臨床 閉塞性動脈硬化症 臨床像の変遷. Medicina (Mex) 2000 ; 37 : 728-730.
 
3) Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia : Revised version. J Vasc Surg 1997 ; 26 : 517-538.
PubMed
4) Yao ST, Hobbs JT, Irvine WT. Ankle systolic pressure measurements in arterial disease affecting the lower extremities. Br J Surg 1969 ; 56 : 676-679.
PubMed
5) Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline) : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines : developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. J Vasc Surg 2011 ; 54 : e32-e58.
 
6) Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). Vasc Surg 2000 ; 31 : S1-S296.
 
7) Norgren L, Hiatt WR, Dormandy JA, et al. Intersociety consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007 ; 45 : S5-S67.
 
8) Haimovici H : Muscular, renal, and metabolic complications of acute arterial occlusions : Myonephropathicmetabolic syndrome. Surgery 1979 ; 85 : 461-468.
PubMed
9) Stewart KJ, Hiatt WR, Regensteiner JG, et al. Exercise training for claudication. N Engl J Med 2002 ; 347 : 1941-1951.
PubMed
10) 藤岡顕太郎, 江里健輔, 中島伸之, 他. 間歇性跛行症例に対する薬効評価法 日本脈管学会間歇性跛行重症度評価小委員会報告. 脈管学 2000 ; 40 : 851-857.
 
11) Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease : The CASTLE study (Cilostazol : A Study in Long-term Effects). J Vasc Surg 2008 ; 47 : 330-336.
PubMed
12) Baigent C, Sudlow C, Collins R, et al. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002 ; 324 : 71-86.
 
13) Gent M, Beaumont D, Blanchard J, et al. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 ; 348 : 1329-1339.
 
14) Shigematsu H, Komori K, Tanemoto K, et al. Clopidogrel for Atherothrombotic Event Management in Patients with Peripheral Arterial Disease (COOPER) Study : Safety and Efficacy of Clopidogrel versus Ticlopidine in Japanese Patients. Ann Vasc Dis 2012 ; 5 : 364-375.
PubMed
15) Klein AJ, Feldman DN, Aronow HD, et al. SCAI expert consensus statement for aorto-iliac arterial intervention appropriate use. Catheter Cardiovasc Interv 2014 ; 84 : 520-528.
PubMed
16) Klein AJ, Pinto DS, Gray BH, et al. SCAI expert consensus statement for femoral-popliteal arterial intervention appropriate use. Catheter Cardiovasc Interv 2014 ; 84 : 529-538.
PubMed
17) 重松宏, 池田康夫, 石丸新, 他. 末梢閉塞性動脈疾患の治療ガイドライン . Circ J 2009 ; 73 (Suppl III) : 1507-1569.
 
18) Dorigo W, Pulli R, Piffaretti G, et al. Results from an Italian multicentric registry comparing heparinbonded ePTFE graft and autologous saphenous vein in below-knee femoro-popliteal bypasses. J Cardiovasc Surg (Torino) 2012 ; 53 : 187-194.
PubMed
19) El-Sayed HF. Bypass surgery for lower extremity limb salvage : vein bypass. Methodist Debakey Cardiovasc J 2012 ; 8 : 37-42.
PubMed
20) Desy NM, Spinner RJ. The etiology and management of cystic adventitial disease. J Vasc Surg 2014 ; 60 : 235-245.
 
21) Noorani A, Walsh SR, Cooper DG, et al. Entrapment syndromes. Eur J Vasc Endovasc Surg 2009 ; 37 : 213-220.
PubMed

2部 血小板

P.130 掲載の参考文献
1) 内山真一郎. 虚血性脳血管障害. In : 池田康夫, 丸山征郎 (編). 血小板生物学, 東京 : メディカルレビュー社, 2004 : 675-694.
 
2) 内山真一郎. 血液凝固能. In : 橋本信夫 (編). 脳神経外科学体系, 東京 : 中山書店, 2004 : 32-44.
 
3) World Health Organization. Fact Sheets. Media Center 2014.
 
4) 内山真一郎. 健康に生きる. In : 矢崎義雄 (編). 医の未来, 東京 : 岩波書店, 2012 : 167-183.
 
5) Kubo M, Hata J, Doi Y, et al. Secular trends in the incidence of and risk factors for ischemic stroke and its subtypes in Japanese population. Circulation 2008 ; 118 : 2672-2678.
PubMed
6) 内山真一郎. アテローム血栓症の抗血小板療法を評価する. Vasc Med 2005 ; 1 : 53-62.
 
7) 内山真一郎. アスピリンの一次・二次予防効果のエビデンス. 薬局 2013 ; 64 : 276-284.
Medical*Online
8) 杉本充彦. 血栓形成過程 : オーバービュー. J Jpn Coll Angiol 2011 ; 51 : 275-282.
 
9) Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996 ; 84 : 289-297.
PubMed
10) Sugimoto M, Miyata S. Functional property of von Willebrand factor under flowing blood. Int J Hematol 2002 ; 75 : 19-24.
 
11) 内山真一郎. 血小板活性化と血液凝血学的異常. 神経内科 2000 ; 52 : 10-17.
 
12) Grawaz M, Langer H, May AE. Platelet in inflammation and atherogenesis. J Clin Invest 2005 ; 115 : 3378-3384.
 
13) Frenette PS, Johnson RC, Hynes RO, et al. Platelet roll on stimulated endothelium in vivo : an interaction mediated by endothelial P-selectin. Proc Nat Acad Sci USA 1995 ; 92 : 7450-7454.
PubMed
14) Romo GM, Dong JF, Schade AJ, et al. The glycoprotein Ib-IX-V complex is a platelet counter receptor for P-selection. J Exp Med 1999 ; 190 : 803-814.
 
15) Frenette PS, Denis CV, Weiss L, et al. P-selection glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med 2000 ; 191 : 13-22.
 
16) Bombeli T, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothelial cells evidence for a Gp IIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule-1 (ICAM-1), αvβ3 integrin, and GpIb α. J Exp Med 1998 ; 187 : 329-339.
 
17) Hawrylowicz CM, Howells GL, Feldmann M. Plateletderived interleukin 1 induces human endothelial adhesion molecule expression and cytokine production. J Exp Med 1991 ; 174 : 785-790.
PubMed
18) Weyrich AS, Elstad MR, McEver RP, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996 ; 97 : 1525-1534.
PubMed
19) Massberg S, Brand K, Gruner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002 ; 196 : 887-896.
 
20) Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood 2003 ; 101 : 2290-2295.
 
21) Mach F, Schonbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998 ; 394 : 200-203.
PubMed
22) Uchiyama S, Nakamura T, Yamazaki M, et al. New modalities and aspects of antiplatelet therapy for stroke prevention. Cerebrovasc Dis 2006 ; 21 (Suppl 1) : 7-16.
 
23) Antithrmbotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease : collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009 ; 373 : 1849-1860.
PubMed
24) Uchiyama S. Clopidogrel resistance : identifying and overcoming a barrier to effective antiplatelet treatment. Cardiovasc Ther 2011 ; 29 : e100-e111.
PubMed
25) Uchiyama S, Demaershalk BM, Goto S, et al. Stroke prevention by cilostazol in patients with atherothrombosis : meta-analysis of placebo-controlled randomize trials. J Stroke Cerebrovasc Dis 2009 ; 18 : 382-390.
 
26) Yousuf O, Bhatt DL. The evolution of antiplatelet therapy in cardiovascular disease. Nat Rev Cardiol 2011 ; 8 : 547-559.
PubMed
27) 内山真一郎. 期待される抗血小板薬. 循環器内科 2010 ; 68 : 372-376.
 
28) Cattano M. New P2Y12 inhibitors. Circulation 2010 ; 121 : 171-179.
 
P.136 掲載の参考文献
1) Battinelli EM, Hartwig JH, Italiano JEJr. Delivering new insight into the biology of megakaryopoiesis and thrombopoiesis. Curr Opin Hematol 2007 ; 14 : 419-426.
 
2) Chang Y, Bluteau D, Debili N, et al. From hematopoietic stem cells to platelets. Journal of thrombosis and haemostasis. JTH 2007 ; 5 Suppl 1 : 318-327.
 
3) Geddis AE. Megakaryopoiesis. Semin Hematol 2010 ; 47 : 212-219.
PubMed
4) Coller BS. A Brief History of ideas about platelets in health and disease. Platelets. ed. Michelson AD., Academic Press, xxiii-xii (i foreword), 2006
 
5) Kaushansky K. Historical review : megakaryopoiesis and thrombopoiesis. Blood 2008 ; 111 (3) : 981-986.
PubMed
6) Wright JH. The origin and nature of the blood plates. Boston Med Surg J 1906 ; 23 : 643-645.
 
7) Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994 ; 77 : 1117-1124.
PubMed
8) Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994 ; 369 : 568-571.
 
9) Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin : a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A 1994 ; 91 : 11104-11108.
PubMed
10) Kato T, Ogami K, Shimada Y, et al. Purification and characterization of thrombopoietin. J Biochem 1995 ; 118 : 229-236.
PubMed
11) Shivdasani RA. Molecular and transcriptional regulation of megakaryocyte differentiation. Stem Cells 2001 ; 19 : 397-407.
 
12) Avanzi MP, Mitchell WB. Ex Vivo production of platelets from stem cells. Br J Haematol 2014 Feb 13.
 
13) Sanjuan-Pla A, Macaulay IC, Jensen CT, et al. Plateletbiased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. Nature 2013 ; 502 (7470) : 232-236.
PubMed
14) Yu M, Cantor AB. Megakaryopoiesis and thrombopoiesis : an update on cytokines and lineage surface markers. Methods Mol Biol 2012 ; 788 : 291-303.
PubMed
15) Kosaki G. In vitro platelet production from mature megakaryocytes : does platelet release occur via proplatelets? Int J Hematol 2005 ; 81 : 208-219.
PubMed
16) Junt T, Schulze H, Chen Z, et al. Dynamic visualization of thrombopoesis within bone marrow. Science 2007 ; 317 : 1767-1770.
 
17) トロンボポエチン受容体作動薬のすべて, 東京, 先端医学社, 2012.
 
18) Avecilla ST, Hattori K, Heissig B, et al. Chemokinemediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 2004 ; 10 (1) : 64-71.
PubMed
19) Salim JP, Goette NP, Lev PR, et al. Dysregulation of stromal derived factor 1/CXCR4 axis in the megakaryocytic lineage in essential thrombocythemia. Br J Haematol 2009 ; 144 (1) : 69-77.
PubMed
20) Dore LC, Crispino JD. Transcription factor networks in erythroid cell and megakaryocyte development. Blood 2011 ; 14 ; 118 (2) : 231-239.
 
21) Ravid K, Doi T, Beeler DL, et al. Transcriptional regulation of the rat platelet factor 4 gene : interaction between an enhancer/silencer domain and the GATA site. Mol Cell Biol 1991 ; 11 (12) : 6116-6127.
PubMed
22) Martin F, Prandini MH, Thevenon D,et al. The transcription factor GATA-1 regulates the promoter activity of the platelet glycoprotein IIb gene. J Biol Chem 1993 ; 268 (29) : 21606-21612.
 
23) Lemarchandel V, Ghysdael J, Mignotte V,et al. GATA and Ets cis-acting sequences mediate megakaryocytespecific expression. Mol Cell Biol 1993 ; 13 (1) : 668-676.
PubMed
24) Vicente C, Conchillo A, Garcia-Sanchez MA,et al. The role of the GATA2 transcription factor in normal and malignant hematopoiesis. Crit Rev Oncol Hematol 2012 ; 82 : 1-17.
PubMed
25) Ono Y, Wang Y, Suzuki H, et al. (2012) Induction of functional platelets from mouse and human fibroblasts by p45NF-E2/Maf. Blood 120 : 3812-3821.
PubMed
26) Matsubara Y, Murata M, Ikeda Y. Culture of megakaryocytes and platelets from subcutaneous adipose tissue and a preadipocyte cell line. Methods Mol Biol 2012 ; 788 : 249-258.
 
27) Matsubara Y, Ono Y, Suzuki H, et al. OP9 bone marrow stromal cells differentiate into megakaryocytes and platelets. Plos One. 2013 ; 8 : e58123.
PubMed
28) Lu J, Guo S, Ebert BL, et al. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell 2008 ; 14 : 843-853.
 
29) Edelstein LC, McKenzie SE, Shaw C, et al. MicroRNAs in platelet production and activation. J Thromb Haemost 2013 ; 11 Suppl 1 : 340-350.
 
30) Girardot M, Pecquet C, Boukour S, et al. miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. Blood 2010 ; 116 (3) : 437-445.
 
P.144 掲載の参考文献
1) Suzuki H, Yamazaki H, Tanoue, K. Immunocytochemical aspects of platelet adhesive proteins and membrane glycoproteins during activation. Prog Histochem Cytochem 1996 ; 30 : 1-109.
PubMed
2) White JG. Platelet structure. In : Michelson AD. ed. Platelets. IInd edition, Burlington, MA : Academic Press. 2006 : 45-73.
 
3) van Nispen tot Pannerden H, de Haas F, Geerts W, et al. The platelet interior revisited : electron tomography reveals tubular α -granule subtypes. Blood 2010 ; 116 : 1147-1156.
 
4) Urban D, Li L, Christensen H, et al. The VPS33Bbinding protein VPS16B is required in megakaryocyte and platelet α -granule biogenesis. Blood 2012 ; 120 : 5032-5040.
 
5) Peters CG, Michelson AD, Flaumenhaft R. Granule exocytosis is required for platelet spreading : differential sorting of α -granules expressing VAMP-7. Blood 2012 ; 120 : 199-206.
 
6) Maynard DM, Heijnen HF, Horne MK, et al. Proteomic analysis of platelet α-granules using mass spectrometry. J Thromb Haemost 2007 ; 5 : 1945-1955.
 
7) Suzuki H, Murasaki K, Kodama K, et al. Intracellular localization of glycoprotein VI in human platelets and its surface expression upon activation. Br J Haematol 2003 ; 121 : 904-912.
PubMed
8) Nurden P, Poujol C, Winckler J, et al. Immunolocalization of P2Y1 and TPα receptors in platelets showed a major pool associated with the membranes of α-granules and the open canalicular system. Blood 203 ; 101 : 1400-1408.
 
9) Heijnen HF, Oorschot V, Sixma JJ, et al. Thrombin stimulates glucose transport in human platelets via the translocation of the glucose transporter GLUT-3 from α-granules to the cell surface. J Cell Biol 1997 ; 138 : 323-330.
 
10) Maynard DM, Heijnen HF, Gahl WA, et al. The α-granule proteome : novel proteins in normal and ghost granules in gray platelet syndrome. J Thromb Haemost 2010 ; 8 : 1786-1796.
 
11) Golebiewska EM, Poole AW. Secrets of platelet exocytosis-what do we really know about platelet secretion mechanisms? Br J Haematol 2013 ; 165 : 204-216.
PubMed
12) White JG. Platelet interior imaging technologies. Blood 2010 ; 116 : 6150-6151.
PubMed
13) Ge S, Woo E, Haynes CL. Quantal regulation and exocytosis of platelet dense-body granules. Biophys J 2011 ; 101 : 2351-2359.
PubMed
14) McNicol A, Israels SJ. Platelet dense granules : structure, function and implications for haemostasis. Thromb Res 1999 ; 95 : 1-18.
PubMed
15) Weiss HJ, Lages B, Vicic W, et al. Heterogeneous abnormalities of platelet dense granule ultrastructure in 20 patients with congenital storage pool deficiency. Br J Haematol 1993 ; 83 : 282-295.
PubMed
16) Dolan AT, Diamond SL. Systems modeling of Ca2+ homeostasis and mobilization in platelets mediated by IP3 and store-operated Ca2+ entry. Biophys J 2014 ; 106 : 2049-2060.
PubMed
17) Ebbeling L, Robertson C, McNicol A, et al. Rapid ultrastructural changes in the dense tubular system following platelet activation. Blood 1992 ; 80 : 718-723.
PubMed
18) Hartwig JH. The platelet cytoskeleton. In : Michelson AD. ed. Platelets. IInd edition, Burlington, MA : Academic Press ; 2006 : 75-97.
 
19) Pleines I, Dutting S, Cherpokova D, et al. Defective tubulin organization and proplatelet formation in murine megakaryocytes lacking Rac1 and Cdc42. Blood 2013 ; 122 : 3178-3187.
PubMed
20) Italiano JE. Unraveling mechanisms that control platelet production. Semin Thromb Hemost 2013 ; 39 : 15-24.
PubMed
21) Kunishima S, Nishimura S, Suzuki H, et al. TUBB1 mutation disrupting microtubule assembly impairs proplatelet formation and results in congenital macrothrombocytopenia. Eur J Haematol 2014 ; 92 : 276-282.
PubMed
22) 鈴木英紀. 血小板活性化とシグナル伝達. 顕微鏡 2005 ; 40 : 124-127.
 
23) Patel-Hett S, Wang H, Begonja AJ, et al. The spectrinbased membrane skeleton stabilizes mouse megakaryocyte membrane systems and is essential for proplatelet and platelet formation. Blood 2011 ; 118 : 1641-1652.
PubMed
24) Cerecedo D. Platelet cytoskeleton and its hemostatic role. Blood Coagul Fibrinolysis 2013 ; 24 : 798-808.
PubMed
25) Plow EF, Pesho MM, Ma Y. Integrin α IIbβ3. In : Michelson AD. ed. Platelets. IInd edition, Burlington, MA : Academic Press ; 2006 : 165-178.
 
26) Suzuki H, Yamazaki H, Tanoue K. Immunocytochemical studies on colocalization of α-granule membrane α IIb β 3 integrin and intragranular fibrinogen of human platelets and their cell-surface expression during the thrombin-induced release reaction. J Electron Microsc 2003 ; 52 : 183-195.
 
27) Kunishima S, Kashiwagi H, Otsu M, et al. Heterozygous ITGA2B R995W mutation inducing constitutive activation of the α IIb β 3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia. Blood 2011 ; 117 : 5479-5484.
 
28) Nurden AT, Pillois X, Fiore M, et al. Glanzmann thrombasthenia-like syndromes associated with macrothrombocytopenias and mutations in the genes encoding the α IIb β 3 integrin. Semin Thromb Hemost 2011 ; 37 : 698-706.
 
29) Kashiwagi H, Kunishima S, Kiyomizu K, et al. Demonstration of novel gain-of-function mutations of α IIb β 3 : association with macrothrombocytopenia and glanzmann thrombasthenia-like phenotype. Mol Genet Genomic Med 2013 ; 1 : 77-86.
 
30) Kato K, Martinez C, Russell S, et al. Genetic deletion of mouse platelet glycoprotein Ibβ produces a Bernard-Soulier phenotype with increased α-granule size. Blood 2004 ; 104 : 2339-2344.
 
31) Watanabe R, Ishibashi T, Saitoh Y, et al. Bernardsoulier syndrome with a homozygous 13 base pair deletion in the signal peptide-coding region of the platelet glycoprotein Ibβ gene. Blood Coagul Fibrinolysis 2003 ; 14 : 387-394.
 
32) 鈴木英紀. 先天性血小板機能異常症/storage pool病. in坂田洋一, 小澤敬也, 編. 別冊・医学のあゆみ 血液疾患-state of arts Ver.3 ; 医歯薬出版 2005 : 733-736.
 
33) Gunay-Aygun M, Zivony-Elboum Y, Gumruk F, et al. Gray platelet syndrome : natural history of a large patient cohort and locus assignment to chromosome 3p. Blood 2010 ; 116 : 4990-5001.
PubMed
34) Kunishima S, Kojima T, Matsushita T, et al. Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome). Blood 2001 ; 97 : 1147-1149.
PubMed
35) Kunishima S, Matsushita T, Yoshihara T, et al. First description of somatic mosaicism in MYH9 disorders. Br J Haematol 2005 ; 128 : 360-365.
PubMed
36) Chen Y, Boukour S, Milloud R, et al. The abnormal proplatelet formation in MYH9-related macrothrombocytopenia results from an increased actomyosin contractility and is rescued by myosin IIA inhibition. J Thromb Haemost 2013 ; 11 : 2163-2175.
PubMed
37) Nurden P, Chretien F, Poujol C, et al. Platelet ultrastructural abnormalities in three patients with type 2B von Willebrand disease. Br J Haematol 2000 ; 110 : 704-714.
PubMed
38) Nurden P, Gobbi G, Nurden A, et al. Abnormal VWF modifies megakaryocytopoiesis : studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B. Blood 2010 ; 115 : 2649-2656.
PubMed
39) Nurden P, Nurden AT, La Marca S, et al. Platelet morphological changes in 2 patients with von Willebrand disease type 3 caused by large homozygous deletions of the von Willebrand factor gene. Haematologica 2009 ; 94 : 1627-1629.
PubMed
P.152 掲載の参考文献
1) Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor Cell 1996 ; 84 : 289-297.
PubMed
2) Tsuji S, Sugimoto M, Miyata S, et al. Real-time analysis of mural thrombus formation in various platelet aggregation disorders : Distinct shear-dependent roles of platelet receptors and adhesive proteins under flow. Blood 1999 ; 94 : 968-975.
PubMed
3) Sugimoto M, Tsuji S, Kuwahara M, et al. Sheardependent functions of the interaction between soluble von Willebrand factor and platelet glycoprotein Ib in mural thrombus formation on a collagen surface. Int J Hematol 1999 ; 69 : 48-53.
PubMed
4) Sugimoto M, Miyata S. Functional property of von Willebrand factor under flowing blood. Int J Hematol 2002 ; 75 : 19-24.
 
5) Kuwahara M, Sugimoto M, Tsuji S, et al. Cytosolic calcium changes in a process of platelet adhesion and cohesion on a von Willebrand factor-coated surface under flow conditions. Blood 1999 ; 94 : 1149-1155.
 
6) Kuwahara M, Sugimoto M, Tsuji S, et al. Platelet shape changes and adhesion under high shear flow. Arterioscler Thromb Vasc Biol 2002 ; 222 : 329-334.
 
7) Matsui H, Sugimoto M, Mizuno T, et al. Distinct and concerted functions of von Willebrand factor and fibrinogen in mural thrombus growth under high shear flow. Blood 2002 ; 100 : 3604-3610.
PubMed
8) Shida Y, Nishio K, Sugimoto M, et al. Functional imaging of shear-dependent activity of ADAMTS13 in regulating mural thrombus growth under whole blood flow conditions. Blood 2008 ; 111 : 1295-1298.
PubMed
9) Hobbs, II WE, Lopez JA. Shear elegance : regulation of thrombus growth by shear stress. Blood 2008 ; 111 : 972.
 
10) Neeves KB, McCarty OJ, Reininger AJ, et al. Flowdependent thrombin and fibrin generation in vitro : opportunities for standardization ; J Thromb Haemost 2014 ; 12 : 418-420.
PubMed
11) Nesbitt WS, Westein E, Tovar-Lopez FJ, et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nature Med 2009 ; 15 : 665-673.
PubMed
P.157 掲載の参考文献
1) Nieswandt B, Watson SP. Platelet-collagen interaction : Is gpvi the central receptor? Blood 2003 ; 102 : 449-461.
PubMed
2) Suzuki-Inoue K, Inoue O, Ozaki Y. Novel platelet activation receptor clec-2 : From discovery to prospects. J Thromb Haemost 2011 ; 9 (Suppl 1) : 44-55.
 
3) Crittenden JR, Bergmeier W, Zhang Y, et al. Caldaggefi integrates signaling for platelet aggregation and thrombus formation. Nat Med 2004 ; 10 : 982-986.
PubMed
4) Stefanini L, Bergmeier W. Caldag-gefi and platelet activation. Platelets 2010 ; 21 : 239-243.
PubMed
5) Watanabe N, Bodin L, Pandey M, et al. Mechanisms and consequences of agonist-induced talin recruitment to platelet integrin alphaiibbeta3. J Cell Biol 2008 ; 181 : 1211-1222.
PubMed
6) Tadokoro S, Shattil SJ, Eto K, et al. Talin binding to integrin beta tails : A final common step in integrin activation. Science 2003 ; 302 : 103-106.
PubMed
7) Moser M, Nieswandt B, Ussar S, et al. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med 2008 ; 14 : 325-330.
PubMed
8) Nesbitt WS, Westein E, Tovar-Lopez FJ, et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 2009 ; 15 : 665-673.
PubMed
9) 大森司. 抗血小板薬抵抗性の概念とその実態. 医学の歩み 2009 ; 228 : 1001-1006.
 
10) Patil S, Newman DK, Newman PJ. Platelet endothelial cell adhesion molecule-1 serves as an inhibitory receptor that modulates platelet responses to collagen. Blood 2001 ; 97 : 1727-1732.
PubMed
11) Newman DK, Hamilton C, Newman PJ. Inhibition of antigen-receptor signaling by platelet endothelial cell adhesion molecule-1 (cd31) requires functional itims, shp-2, and p56 (lck). Blood 2001 ; 97 : 2351-2357.
PubMed
12) 田所誠司. 血小板インテグリンの負の調節因子. Annual Review血液 2013 ; 2013 : 175-181.
Medical*Online
13) Tadokoro S, Nakazawa T, Kamae T, et al. A potential role for alpha-actinin in inside-out alphaiibbeta3 signaling. Blood 2011 ; 117 : 250-258.
PubMed
14) Rantala JK, Pouwels J, Pellinen T, et al. Sharpin is an endogenous inhibitor of beta1-integrin activation. Nat Cell Biol 2011 ; 13 : 1315-1324.
PubMed
15) 井上克枝. 血小板の活性化と制御機構. 日本臨牀 2014 ; 72 : 1212-1217.
 
P.162 掲載の参考文献
1) 後藤信哉. 血小板細胞シミュレーションモデル. 日本血栓止血学会雑誌 2010 ; 21 : 334-336.
 
2) Goto S, Ikeda Y, Saldivar, et al. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. The Journal of clinical investigation 1998 ; 101 : 479-486.
PubMed
3) Goto S, Kasahara H, Sakai H, et al. Functional compensation of the low platelet count by increased individual platelet size in a patient with may-hegglin anomaly presenting with acute myocardial infarction. International journal of cardiology 1998 ; 64 : 171-177.
 
4) Goto S, Tamura N, Eto K, et al. Functional significance of adenosine 5'-diphosphate receptor (p2y (12)) in platelet activation initiated by binding of von willebrand factor to platelet gp ibalpha induced by conditions of high shear rate. Circulation 2002 ; 105 : 2531-2536.
PubMed
5) Goto S, Tamura N, Handa S, et al. Involvement of glycoprotein vi in platelet thrombus formation on both collagen and von willebrand factor surfaces under flow conditions. Circulation 2002 ; 106 : 266-272.
PubMed
6) Goto S, Tamura N, Ishida H. Ability of anti-glycoprotein iib/iiia agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. Journal of the American College of Cardiology 2004 ; 44 : 316-323.
PubMed
7) Goto S, Tamura N, Ishida H, et al. Dependence of platelet thrombus stability on sustained glycoprotein iib/iiia activation through adenosine 5' -diphosphate receptor stimulation and cyclic calcium signaling. Journal of the American College of Cardiology 2006 ; 47 : 155-162.
PubMed
8) Tamura N, Kitajima I, Kawamura Y, et al. Important regulatory role of activated platelet-derived procoagulant activity in the propagation of thrombi formed under arterial blood flow conditions. Circulation journal : official journal of the Japanese Circulation Society 2009 ; 73 : 540-548.
PubMed
9) Tomita A, Tamura N, Nanazawa Y, et al. Development of virtual platelets implementing the functions of three platelet membrane proteins with different adhesive characteristics. Journal of atherosclerosis and thrombosis 2014.
PubMed
10) Miyazaki H, Yamaguchi T. Formation and destruction of primary thrombi under the influence of blood flow and von willebrand factor analyzed by a discrete element method. Biorheology 2003 ; 40 : 265-272.
PubMed
P.168 掲載の参考文献
1) Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nature Medicine 2009 ; 15 : 914-920.
PubMed
2) Nishimura S, Manabe I, Nagasaki M, et al. In vivo imaging in mice reveals local cell dynamics and inflammation in obese adipose tissue. J Clin Invest 2008 ; 118 (2) : 710-721.
PubMed
3) Nishimura S*, Takizawa H*,Takayama N, et al (*equal contribution). Lnk regulates integrin α IIb β 3 outside-in signaling in mouse platelets, leading to stabilization of thrombus development in vivo. J Clin Invest 2010 ; 120 (1) : 179-190.
 
4) Nishimura S, Manabe I, Nagasaki M, et al. In vivo imaging visualizes discoid platelet aggregations without endothelium disruption and implicates contribution of inflammatory cytokine and integrin signaling. Blood 2012 ; 119 (8) : e45-e56.
PubMed
5) Takizawa H, Nishimura S, Takayama N, et al. Lnk regulates integrin α IIb β 3 outside-in signaling in mouse platelets, leading to stabilization of thrombus development in vivo. J Clin Invest 2010 ; 120 (1) : 179-190.
 
6) Takayama N, Nishimura S, Nakamura S, et al. Transient activation of c-MYC expression is critifal for efficient platelet generation from human induced pluripotent stem cells. J Exp Med 2010 ; 207 (13) : 2817-2830.
PubMed
7) Nakamura S, Takayama N, Hirata S, et al. Expandable Megakaryocyte Cell Lines Enable Clinically Applicable Generation of Platelets from Human Induced Pluripotent Stem Cells. Cell Stem Cell 2014 in publication.
 
P.178 掲載の参考文献
1) Nurden AT, Nurden P. Congenital platelet disorders and understanding of platelet function. Br J Haematol 2014 ; 165 (2) : 165-178.
PubMed
2) Freson K, Wijgaerts A, van Geet C. Update on the causes of platelet disorders and functional consequences. Int J Lab Hematol 2014 ; 36 (3) : 313-325.
PubMed
3) 柏木浩和, 冨山佳昭. 血小板機能異常症. In : 金倉譲, 冨山佳昭 (編). よくわかる血栓・止血異常の臨床. 初版. 中山書店 : 東京, 2014 : 92-104.
 
4) Lanza F. Bernard-Soulier syndrome (hemorrhagiparous thrombocytic dystrophy). Orphanet J Rare Dis 2006 ; 1 : 46.
PubMed
5) Li R, Emsley J. The organizing principle of the platelet glycoprotein Ib-IX-V complex. J Thromb Haemost 2013 ; 11 (4) : 605-614.
PubMed
6) 國島伸治. 先天性血小板減少症の診断と分子病態. 臨床血液 2014 ; 55 : 882-892.
 
7) Arthur JF, Dunkley S, Andrews RK. Platelet glycoprotein VI-related clinical defects. Br J Haematol 2007 ; 139 (3) : 363-372.
PubMed
8) Akiyama M, Kashiwagi H, Todo K, et al. Presence of platelet-associated anti-glycoprotein (GP) VI autoantibodies and restoration of GPVI expression in patients with GPVI deficiency. J Thromb Haemost 2009 ; 7 (8) : 1373-1383.
PubMed
9) Nurden AT, Fiore M, Nurden P, et al. Glanzmann thrombasthenia : a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 2011 ; 118 (23) : 5996-6005.
PubMed
10) Ruiz C, Liu CY, Sun QH, et al. A point mutation in the cysteine-rich domain of glycoprotein ( GP) IIIa results in the expression of a GPIIb-IIIa (α IIbβ 3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype. Blood 2001 ; 98 (8) : 2432-2441.
 
11) Fang J, Nurden P, North P, et al. C560Rβ 3 caused platelet integrin α II b β 3 to bind fibrinogen continuously, but resulted in a severe bleeding syndrome and increased murine mortality. J Thromb Haemost 2013 ; 11 (6) : 1163-1171.
 
12) Kashiwagi H, Kunishima S, Kiyomizu K, et al. Demonstration of novel gain-of-function mutations of α IIbβ 3 : association with macrothrombocytopenia and glanzmann thrombasthenia-like phenotype. Mol Genet Genomic Med 2013 ; 1 (2) : 77-86.
 
13) Moser M, Nieswandt B, Ussar S, et al. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med 2008 ; 14 (3) : 325-330.
PubMed
14) van de Vijver E, Maddalena A, Sanal O, et al. Hematologically important mutations : leukocyte adhesion deficiency (first update). Blood Cells Mol Dis 2012 ; 48 (1) : 53-61.
PubMed
15) Crittenden JR, Bergmeier W, Zhang Y, et al. CalDAGGEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med 2004 ; 10 (9) : 982-986.
PubMed
16) Canault M, Ghalloussi D, Grosdidier C, et al. Human CalDAG-GEFI gene (RASGRP2) mutation affects platelet function and causes severe bleeding. J Exp Med 2014 ; 211 (7) : 1349-1362.
PubMed
17) Kamae T, Kiyomizu K, Nakazawa T, et al. Bleeding tendency and impaired platelet function in a patient carrying a heterozygous mutation in the thromboxane A2 receptor. J Thromb Haemost 2011 ; 9 (5) : 1040-1048.
 
18) Gunay-Aygun M, Falik-Zaccai TC, Vilboux T, et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α -granules. Nat Genet 2011 ; 43 (8) : 732-734.
 
19) Albers CA, Cvejic A, Favier R, et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet 2011 ; 43 (8) : 735-737.
PubMed
20) Kahr WH, Hinckley J, Li L, et al. Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nat Genet 2011 ; 43 (8) : 738-740.
PubMed
21) Deppermann C, Cherpokova D, Nurden P, et al. Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice. J Clin Invest 2013 ; 123 (8) : 3331-3342.
PubMed
22) Kahr WH, Lo RW, Li L, et al. Abnormal megakaryocyte development and platelet function in Nbeal2 (-/-) mice. Blood 2013 ; 122 (19) : 3349-3358.
 
23) Whiteheart SW. α -Granules at the BEACH. Blood 2013 ; 122 (19) : 3247-3248.
 
24) Monteferrario D, Bolar NA, Marneth AE, et al. A dominant-negative GFI1B mutation in the gray platelet syndrome. N Engl J Med 2014 ; 370 (3) : 245-253.
PubMed
25) Noris P, Biino G, Pecci A, et al. Platelet diameters in inherited thrombocytopenias : analysis of 376 patients with all known disorders. Blood 2014 ; 124 (6) : e4-10.
PubMed
26) Balduini CL, Pecci A, Savoia A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol 2011 ; 154 (2) : 161-174.
PubMed
27) Pecci A, Klersy C, Gresele P, et al. MYH9-related disease : a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations. Hum Mutat 2014 ; 35 (2) : 236-247.
PubMed
28) Pecci A, Malara A, Badalucco S, et al. Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation. Thromb Haemost 2009 ; 102 (1) : 90-96.
PubMed
29) Ghevaert C, Salsmann A, Watkins NA, et al. A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the alphaIIbbeta3 integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia. Blood 2008 ; 111 (7) : 3407-3414.
PubMed
30) Kunishima S, Kashiwagi H, Otsu M, et al. Heterozygous ITGA2B R995W mutation inducing constitutive activation of the α IIbβ 3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia. Blood 2011 ; 117 (20) : 5479-5484.
 
31) Kunishima S, Kobayashi R, Itoh TJ, et al. Mutation of the beta1-tubulin gene associated with congenital macrothrombocytopenia affecting microtubule assembly. Blood 2009 ; 113 (2) : 458-461.
PubMed
32) Kunishima S, Nishimura S, Suzuki H, et al. TUBB1 mutation disrupting microtubule assembly impairs proplatelet formation and results in congenital macrothrombocytopenia. Eur J Haematol 2014 ; 92 (4) : 276-282.
PubMed
33) Kunishima S, Okuno Y, Yoshida K, et al. ACTN1 mutations cause congenital macrothrombocytopenia. Am J Hum Genet 2013 ; 92 (3) : 431-438.
PubMed
P.185 掲載の参考文献
1) Devaux PF, Herrmann A, Ohlwein N, et al. How lipid flippases can modulate membrane structure. Biochim Biophys Acta 2008 ; 1778 : 1591-1600.
PubMed
2) Zwaal RFA, Comfurius P, Bevers EM. Scott syndrome, a bleeding disorder caused by defective scrambling of membrane phospholipids. Biochim Biophys Acta 2004 ; 136 : 119-128.
 
3) Bevers EM, Williamson PL. Phospholipid scramblase : an update. FEBS Lett 2010 ; 584 : 2724-2730.
PubMed
4) Bachelot-Loza C, Badol P, Brohard-Bohn B, et al. Differential regulation of platelet aggregation and aminophospholipid exposure by calpain. Br J Haematol 2006 ; 133 : 419-426.
PubMed
5) Rukoyatkina N, Begonja AJ, Geiger J, et al. Phosphatidylserine surface expression and integrin α IIb β 3 activity on thrombin/convulxin stimulated platelets/particles of different sizes. Br J Haematol 2008 ; 144 : 591-602.
 
6) Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002 ; 88 : 186-193.
PubMed
7) Weiss HJ, Vicic WJ, Lages BA, et al. Isolated deficiency of platelet procoagulant activity. Am J Med 1979 ; 67 : 206-213.
PubMed
8) Miletich JP, Kane WH, Hofmann SL, et al. Deficiency of factor Xa-factor Va binding sites on the platelets of a patients with a bleeding disorder. Blood 1979 ; 54 : 1015-1022.
PubMed
9) Rosing J, Bevers EM, Comfurius P, et al. Impaired factor X and prothrombin activation associated with decreased phospholipids exposure in platelets from a patient with a bleeding disorder. Blood 1985 ; 65 : 1557-1561.
PubMed
10) Sims PJ, Wiedmer T, Esmon CT, et al. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome : an isolated defect in platelet procoagulant activity. J Biol Chem 1989 ; 264 : 17049-17057.
PubMed
11) Ahmad SS, Rawala-Sheikh R, Ashby B, et al. Platelet receptor-mediated factor X activation by factor IXa. J Clin Invest 1989 ; 84 : 824-828.
PubMed
12) Bevers EM, Wiedmer T, Comfurius P, et al. Defective Ca2+ -induced microvesiculation and deficient expression of procoagulant activity in erythrocytes from a patient with a bleeding disorder : a study of the red blood cells of Scott syndrome. Blood 1992 ; 79 : 380-388.
PubMed
13) Williamson P, Christie A, Kohlin T, et al. Phospholipid scramblase activation pathways in lymphocytes. Biochemistry 2001 ; 40 : 8065-8072.
PubMed
14) Kojima H, Newton-Nash D, Weiss HJ, et al. Production and characterization of transformed B-lymphocytes expressing the membrane defect of Scott syndrome. J Clin Invest 1994 ; 94 : 2237-2244.
PubMed
15) Toti F, Satta N, Fressinaud E, et al. Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood 1996 ; 87 : 1409-1415.
PubMed
16) Munnix ICl, Harmsma M, Giddings JC, et al. Storemediated calcium entry in the regulation of phosphatidylserine exposure in blood cells from Scott patients. Thromb Haemost 2003 ; 89 : 687-695.
 
17) Flores-Nascimento MC, Orsi FL, Yokoyama AP, et al. Diagnosis of Scott syndrome in patient with bleeding disorder of unknown cause. Blood Coagul Fibrinolysis 2012 ; 23 : 75-77.
PubMed
18) Zhao J, Zhou Q, Wiedmer T, et al. Level of expression of phospholipids scramblase regulates induced movement of phosphatidylserine to the cell surface. J Biol Chem 1998 ; 273 : 6603-6606.
 
19) Suzuki J, Umeda M, Sims PJ, et al. Calcium-dependent phospholipids scrambling by TMEM16F. Nature 2010 ; 468 : 834-838.
PubMed
20) Castoldi E, Collins PW, Williamson PL, et al. Compound heterozygosity for 2 novel TMEM16F mutations in a patient with Scott syndrome. Blood 2011 ; 117 : 4399-4400.
 
21) Yang H, Kim A, David T, et al. TMEM16F forms a Ca2+- activated cation channel required for lipid scrambling in platelets during blood coagulation. Cell 2012 ; 151 : 111-122.
 
22) Tien J, Lee HY, Jan YN, et al. Identification of a dimerization domain in the TMEMA calcium-activated chloride channel (CaCC). Proc Natl Acad Sci U S A 2013 ; 110 : 6352-6357.
 
P.194 掲載の参考文献
1) Ginsburg D, Handin RI, Bonthron DT, et al. Human von Willebrand factor ( vWF) : isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985 ; 228 : 1401-1406.
PubMed
2) Kuwano A, Morimoto Y, Nagai T, et al. Precise chromosomal locations of the genes for dentatorubral-pallidoluysian atrophy (DRPLA), von Willebrand factor (F8vWF) and parathyroid hormone-like hormone (PTHLH) in human chromosome 12p by deletion mapping. Hum Genet 1996 ; 97 : 95-98.
PubMed
3) Mancuso DJ, Tuley EA, Westfield LA, et al. Structure of the gene for human von Willebrand factor. J Biol Chem 1989 ; 264 : 19514-19527.
PubMed
4) Patracchini P, Calzolari E, Aiello V, et al. Sublocalization of von Willebrand factor pseudogene to 22q11.22-q11.23 by in situ hybridization in a 46,X, t (X ; 22) (pter ; q11.21) translocation. Hum Genet 1989 ; 83 : 264-266.
 
5) Mancuso DJ, Tuley EA, Westfield LA, et al. Human von Willebrand factor gene and pseudogene : structural analysis and differentiation by polymerase chain reaction. Biochemistry 1991 ; 30 : 253-269.
PubMed
6) Marti T, Rosselet SJ, Titani K, et al. Identification of disulfide-bridged substructures within human von Willebrand factor. Biochemistry 1987 ; 26 : 8099-8109.
PubMed
7) Voorberg J, Fontijn R, Calafat J, et al. Assembly and routing of von Willebrand factor variants : the requirements for disulfide-linked dimerization reside within the carboxy-terminal 151 amino acids. J Cell Biol 1991 ; 113 : 195-205.
PubMed
8) Katsumi A, Tuley EA, Bodo I, et al. Localization of disulfide bonds in the cystine knot domain of human von Willebrand factor. J Biol Chem 2000 ; 275 : 25585-25594.
PubMed
9) Rehemtulla A , Kaufman RJ. Preferred sequence requirements for cleavage of pro-von Willebrand factor by propeptide-processing enzymes. Blood 1992 ; 79 : 2349-2355.
PubMed
10) Jaffe EA, Hoyer LW ,Nachman RL. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci U S A 1974 ; 71 : 1906-1909.
PubMed
11) Nachman R, Levine R, Jaffe EA. Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes. J Clin Invest 1977 ; 60 : 914-921.
PubMed
12) Wagner DD, Olmsted JB , Marder, VJ. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol 1982 ; 95 : 355-360.
PubMed
13) Sporn LA, Marder VJ , Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell 1986 ; 46 : 185-190.
PubMed
14) Cramer EM, Meyer D, le Menn R, et al. Eccentric localization of von Willebrand factor in an internal structure of platelet alpha-granule resembling that of Weibel-Palade bodies. Blood 1985 ; 66 : 710-713.
 
15) Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990 ; 6 : 217-246.
PubMed
16) Mannucci PM, Ruggeri ZM, Pareti FI, et al. 1-Deamino-8-d-arginine vasopressin : a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1977 ; 1 : 869-872.
 
17) Marchese P, Murata M, Mazzucato M, et al. Identification of three tyrosine residues of glycoprotein Ib alpha with distinct roles in von Willebrand factor and alphathrombin binding. J Biol Chem 1995 ; 270 : 9571-9578.
 
18) Scott JP, Montgomery RR, Retzinger GS. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets. J Biol Chem 199 ; 266 : 8149-8155.
 
19) Berndt MC, Du XP, Booth WJ. Ristocetin-dependent reconstitution of binding of von Willebrand factor to purified human platelet membrane glycoprotein Ib-IX complex. Biochemistry 1988 ; 27 : 633-640.
PubMed
20) Fujimura Y, Titani K, Holland LZ, et al. von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem 1986 ; 261 : 381-385.
 
21) Matsushita T, Sadler JE. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor. J Biol Chem 1995 ; 270 : 13406-13414.
PubMed
22) Kroner PA , Frey AB. Analysis of the structure and function of the von Willebrand factor A1 domain using targeted deletions and alanine-scanning mutagenesis. Biochemistry 1996 ; 35 : 13460-13468.
PubMed
23) Matsushita T, Meyer D, Sadler JE. Localization of von willebrand factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-alanine scanning mutagenesis. J Biol Chem 200 ; 275 : 11044-11049.
 
24) Lollar P, Hill-Eubanks DC, Parke CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988 ; 263 : 10451-10455.
 
25) Leyte A, van Schijndel HB, Niehrs C, et al. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 1991 ; 266 : 740-746.
PubMed
26) Yee A, Gildersleeve RD, Gu S, et al. A von Willebrand factor fragment containing the D' D3 domains is sufficient to stabilize coagulation factor VIII in mice. Blood 2014 ; 124 : 445-452.
 
27) Favaloro EJ, Henniker A, Facey D, et al. Discrimination of von Willebrands disease (VWD) subtypes : direct comparison of von Willebrand factor : collagen binding assay (VWF : CBA) with monoclonal antibody (MAB) based VWF-capture systems. Thromb Haemost 2000 ; 84 : 541-547.
PubMed
28) Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994 ; 71 : 520-525.
PubMed
29) von Willebrand factor Variant Database http://vwf.group.shef.ac.uk.
 
30) Johnsen JM, Auer PL, Morrison AC, et al. Common and rare von Willebrand factor (VWF) coding variants, VWF levels, and factor VIII levels in African Americans : the NHLBI Exome Sequencing Project. Blood 2013 ; 122 : 590-597.
PubMed
31) Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998 ; 67 : 395-424.
PubMed
32) Gill JC, Endres-Brooks J, Bauer PJ, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987 ; 69 : 1691-1695.
PubMed
33) Legendre P, Navarrete AM, Rayes J, et al. Mutations in the A3 domain of von Willebrand factor inducing combined qualitative and quantitative defects in the protein. Blood 2013 ; 121 : 2135-2143.
PubMed
34) O'Brien LA, Sutherland JJ, Weaver DF, et al. Theoretical structural explanation for Group I and Group II, type 2A von Willebrand disease mutations. J Thromb Haemost 2005 ; 3 : 796-797.
 
35) Kashiwagi T, Matsushita T, Ito Y, et al. L1503R is a member of group I mutation and has dominant-negative effect on secretion of full-length VWF multimers : an analysis of two patients with type 2A von Willebrand disease. Haemophilia 2008 ; 14 : 556-563.
 
36) Ruggeri ZM, Pareti FI, Mannucci PM, et al. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 1980 ; 302 : 1047-1051.
 
37) Rabinowitz I, Randi AM, Shindler KS, et al. Type IIB mutation His-505-->Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem 1993 ; 268 : 20497-20501.
 
38) Nishino M, Girma JP, Rothschild C, et al. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989 ; 74 : 1591-1599.
PubMed
39) Mazurier C, Dieval J, Jorieux S, et al. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction. Blood 1990 ; 75 : 20-26.
 
40) Mannucci PM, Tamaro G, Narchi G, et al. Lifethreatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Haematol 1987 ; 39 : 467-470.
 
41) Mohri H, Motomura S, Kanamori H, et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998 ; 91 : 3623-3629.
 
42) Casonato A, Sponga S, Pontara E, et al. von Willebrand factor abnormalities in aortic valve stenosis : Pathophysiology and impact on bleeding. Thrombosis and haemostasis 2011 ; 106 : 58-66.
PubMed
43) Heyde E. Gastrointestinal Bleeding in Aortic Stenosis. NEJM 1958 ; 259 : 196-196.
 
44) Makris M, Federici AB, Mannucci PM, et al. The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease. Haemophilia 2015 ; 21 : 338-342.
PubMed
45) Budde U, Scharf RE, Franke P, et al. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993 ; 82 : 1749-1757.
PubMed
46) Budde U, Schaefer G, Mueller N, et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984 ; 64 : 981-985.
PubMed
47) van Genderen PJ, Budde U, Michiels JJ, et al. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol 1996 ; 93 : 962-965.
 
48) van Genderen PJ, Prins FJ, Lucas IS, et al. Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia : normalization after cytoreduction of the increased platelet count. Br J Haematol 1997 ; 99 : 832-836.
PubMed
49) van Genderen PJ, Leenknegt H. Normal binding of plasma von Willebrand factor to platelets in essential thrombocythemia. Am J Hematol ; 1999 61 : 153-154.
PubMed
50) Lopez-Fernandez MF, Lopez-Berges C, Martin R, et al. Abnormal structure of von Willebrand factor in myeloproliferative syndrome is associated to either thrombotic or bleeding diathesis. Thromb Haemost 1987 ; 58 : 753-757.
PubMed
P.202 掲載の参考文献
1) Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008 ; 112 : 11-18.
PubMed
2) Springer TA. von Willebrand factor, Jedi knight of the bloodstream. Blood 2014 ; 124 : 1412-1425.
PubMed
3) 藤村吉博, 松本雅則, 石西綾美, 他. 血栓性血小板減少性紫斑病. 臨床血液 2014 ; 55 : 93-104.
 
4) Moschcowitz E. Hyaline thombosis of the terminal arterioles and capillaries ; a hitherto undescribed disease. Proc NY Pathol Soc 1924 ; 24 : 21-24.
 
5) Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII : von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982 ; 307 : 1432-1435.
PubMed
6) Asada Y, Sumiyoshi A, Hayashi T, et al. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 1985 ; 38 : 469-479.
PubMed
7) Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996 ; 87 : 4223-4234.
PubMed
8) Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996 ; 87 : 4235-4244.
PubMed
9) Soejima K, Mimura N, Hirashima M, et al. A novel human metalloprotease synthesized in the liver and secreted into the blood : possibly, the von Willebrand factor-cleaving protease? J Biochem 2001 ; 130 : 475-480.
PubMed
10) Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving protease ( ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001 ; 276 : 41059-41063.
PubMed
11) Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001 ; 413 : 488-494.
 
12) Akiyama M, Takeda S, Kokame K, et al. Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor. Proc Natl Acad Sci USA 2009 ; 106 : 19274-19279.
PubMed
13) Zhang Q, Zhou YF, Zhang CZ, et al. Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor. Proc Natl Acad Sci USA 2009 ; 106 : 9226-9231.
 
14) Kokame K, Matsumoto M, Fujimura Y, et al. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 2004 ; 103 : 607-612.
PubMed
15) Gao W, Zhu J, Westfield LA, et al. Rearranging exosites in noncatalytic domains can redirect the substrate specificity of ADAMTS proteases. J Biol Chem 2012 ; 287 : 26944-26952.
PubMed
16) Kokame K, Sakata T, Kokubo Y, et al. von Willebrand factor-to-ADAMTS13 ratio increases with age in a Japanese population. J Thromb Haemost 2011 ; 9 : 1426-1428.
 
17) Kokame K, Nobe Y, Kokubo Y, et al. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005 ; 129 : 93-100.
PubMed
18) Kato S, Matsumoto M, Matsuyama T, et al. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 2006 ; 46 : 1444-1452.
PubMed
19) Kokame K, Matsumoto M, Soejima K, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002 ; 99 : 11902-11907.
PubMed
20) Kokame K, Aoyama Y, Matsumoto M, et al. Inherited and de novo mutations of ADAMTS13 in a patient with Upshaw-Schulman syndrome. J Thromb Haemost 2008 ; 6 : 213-215.
 
21) Fujimura Y, Matsumoto M, Isonishi A, et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost 2011 ; 9 (Suppl. 1) : 283-301.
 
22) Eura Y, Kokame K, Takafuta T, et al. Candidate gene analysis using genomic quantitative PCR : identification of ADAMTS13 large deletions in two patients with Upshaw-Schulman syndrome. Mol Genet Genomic Med 2014 ; 2 : 240-244.
PubMed
23) Kokame K, Kokubo Y, Miyata T. Polymorphisms and mutations of ADAMTS13 in the Japanese population and estimation of the number of patients with Upshaw-Schulman syndrome. J Thromb Haemost 2011 ; 9 : 1654-1656.
PubMed
24) Akiyama M, Kokame K, Miyata T. ADAMTS13 P475S polymorphism causes a lowered enzymatic activity and urea lability in vitro. J Thromb Haemost 2008 ; 6 : 1830-1832.
PubMed
25) Akiyama M, Nakayama D, Takeda S, et al. Crystal structure and enzymatic activity of an ADAMTS-13 mutant with the East Asian-specific P475S polymorphism. J Thromb Haemost 2013 ; 11 : 1399-1406.
PubMed
26) Motto DG, Chauhan AK, Zhu G, et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005 ; 115 : 2752-2761.
PubMed
27) Banno F, Kokame K, Okuda T, et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 2006 ; 107 : 3161-3166.
 
28) Fujioka M, Hayakawa K, Mishima K, et al. ADAMTS13 gene deletion aggravates ischemic brain damage : a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood 2010 ; 115 : 1650-1653.
PubMed
29) Doi M, Matsui H, Takeda H, et al. ADAMTS13 safeguards the myocardium in a mouse model of acute myocardial infarction. Thromb Haemost 2012 ; 108 : 1236-1238.
 
30) Yamaguchi Y, Moriki T, Igari A, et al. Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Thromb Res 2011 ; 128 : 169-173.
PubMed
31) South K, Luken BM, Crawley JT, et al. Conformational activation of ADAMTS13. Proc Natl Acad Sci USA 2014 ; 111 : 18578-18583.
PubMed
32) Muia J, Zhu J, Gupta G, et al. Allosteric activation of ADAMTS13 by von Willebrand factor. Proc Natl Acad Sci USA 2014 ; 111 : 18584-18589.
PubMed
P.211 掲載の参考文献
1) Moake JL. Thrombotic microangiopathies. The New England journal of medicine 2002 ; 347 : 589-600.
PubMed
2) Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 1985 ; 38 : 469-479.
PubMed
3) George JN, Nester CM. Syndromes of thrombotic microangiopathy. The New England journal of medicine 2014 ; 371 : 1847-1848.
PubMed
4) Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura : report of 16 cases and review of the literature. Medicine 1966 ; 45 : 139-159.
 
5) Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. The New England journal of medicine 1991 ; 325 : 393-397.
 
6) Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII : von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. The New England journal of medicine 1982 ; 307 : 1432-1435.
PubMed
7) Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. The New England journal of medicine 1998 ; 339 : 1578-1584.
PubMed
8) Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. The New England journal of medicine 1998 ; 339 : 1585-1594.
PubMed
9) Blombery P, Scully M. Management of thrombotic thrombocytopenic purpura : current perspectives. J Blood Med 2014 ; 5 : 15-23.
PubMed
10) Zheng X, Chung D, Takayama TK, et al. Structure of von Willebr and factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001 ; 276 : 41059-41063.
 
11) Uemura M, Tatsumi K, Matsumoto M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005 ; 106 : 922-924.
 
12) Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998 ; 67 : 395-424.
PubMed
13) Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008 ; 112 : 11-18.
PubMed
14) Fujimura Y, Matsumoto M, Isonishi A, et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. Journal of thrombosis and haemostasis : JTH 2011 ; 9 : 283-301.
PubMed
15) Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012 ; 158 : 323-335.
PubMed
16) Matsumoto M, Bennett CL, Isonishi A, et al. Acquired Idiopathic ADAMTS13 Activity Deficient Thrombotic Thrombocytopenic Purpura in a Population from Japan. PLoS One 2012 ; 7 : e33029.
 
17) Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura : a study of 11 cases. Blood 2005 ; 106 : 1932-1937.
PubMed
18) Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011 ; 118 : 1746-1753.
PubMed
19) Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. The New England journal of medicine 2009 ; 361 : 1676-1687.
PubMed
20) Sawai T, Nangaku M, Ashida A, et al. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. Pediatrics international : official journal of the Japan Pediatric Society 2014 ; 56 : 1-5.
PubMed
21) Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolyticuremic syndrome. The New England journal of medicine 2013 ; 368 : 2169-2181.
PubMed
22) Campistol JM, Arias M, Ariceta G, et al. An update for atypical haemolytic uraemic syndrome : diagnosis and treatment. A consensus document. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 2013 ; 33 : 27-45.
 
23) Stuhlinger W, Kourilsky O, Kanfer A, Sraer JD. Letter : Haemolytic-uraemic syndrome : evidence for intravascular C3 activation. Lancet 1974 ; 2 : 788-789.
PubMed
24) Thompson RA, Winterborn MH. Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. Clinical and experimental immunology 1981 ; 46 : 110-119.
PubMed
25) Warwicker P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney international 1998 ; 53 : 836-844.
PubMed
26) Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R. [Hemolytic-uremic syndrome : bilateral necrosis of the renal cortex in acute acquired hemolytic anemia.]. Schweiz Med Wochenschr 1955 ; 85 : 905-909.
PubMed
27) Jodele S, Licht C, Goebel J, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013 ; 122 : 2003-2007.
PubMed
28) Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet journal of rare diseases 2011 ; 6 : 60.
 
29) 吉田瑤子, 藤村吉博. 非典型溶血性尿毒症症候群 (aHUS) の病態と治療戦略. 血液内科 2014 ; 69 : 589-594.
 
30) Ariceta G, Besbas N, Johnson S, et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatric nephrology 2009 ; 24 : 687-696.
PubMed
P.221 掲載の参考文献
1) Warkentin TE. Drug-induced immune-mediated thrombocytopenia--from purpura to thrombosis. N Engl J Med 2007 ; 356 (9) : 891-893.
PubMed
2) Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 ; 141 (2 Suppl) : e495S-e530S.
 
3) Miyata S. Heparin-induced thrombocytopenia. Vox Sang 2009 ; ISBT Science Series 4 : 167-173.
 
4) Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992 ; 68 (1) : 95-96.
PubMed
5) Greinacher A, Potzsch B, Amiral J, et al. Heparinassociated thrombocytopenia : isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994 ; 71 (2) : 247-251.
PubMed
6) Greinacher A, Alban S, Omer-Adam MA,et al. Heparin-induced thrombocytopenia : a stoichiometrybased model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res 2008 ; 122 (2) : 211-220.
PubMed
7) Warkentin TE, Greinacher A. Heparin-Induced Thrombocytopenia. 4th ed. New York : Informa Healthcare ; 2007.
 
8) Reilly MP, Taylor SM, Hartman NK, et al. Heparininduced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood 2001 ; 98 (8) : 2442-2447.
 
9) Warkentin TE, Sheppard JA, Moore JC, et al. Studies of the immune response in heparin-induced thrombocytopenia. Blood 2009 ; 113 (20) : 4963-4969.
PubMed
10) Rauova L, Hirsch JD, Greene TK, et al. Monocytebound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood 2010 ; 116 (23) : 5021-5031.
PubMed
11) Visentin GP, Ford SE, Scott JP, et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994 ; 93 (1) : 81-88.
PubMed
12) Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987 ; 316 (10) : 581-589.
PubMed
13) Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 2001 ; 98 (4) : 1252-1254.
PubMed
14) Potzsch B, Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 2000 ; 343 (7) : 515.
PubMed
15) Warkentin TE, Sheppard JA. Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin. Blood 2014 ; 123 (16) : 2485-2493.
PubMed
16) Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001 ; 344 (17) : 1286-1292.
PubMed
17) Krauel K, Weber C, Brandt S, et al. Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes. Blood 2012 ; 120 (16) : 3345-3352.
PubMed
18) Krauel K, Potschke C, Weber C, et al. Platelet factor 4 binds to bacteria-inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 2011 ; 117 (4) : 1370-1378.
PubMed
19) Jaax ME, Krauel K, Marschall T, et al. Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4. Blood 2013 ; 122 (2) : 272-281.
PubMed
20) Zheng Y, Wang AW, Yu M, et al. B-cell tolerance regulates production of antibodies causing heparininduced thrombocytopenia. Blood 2014 ; 123 (6) : 931-934.
 
21) Zheng Y, Yu M, Podd A, et al. Critical role for mouse marginal zone B cells in PF4/heparin antibody production. Blood 2013 ; 121 (17) : 3484-3492.
 
22) Selleng K, Schutt A, Selleng S, et al. Studies of the anti-platelet factor 4/heparin immune response : adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens. Transfusion 2010 ; 50 (1) : 32-39.
PubMed
23) Greinacher A, Holtfreter B, Krauel K, et al. Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood 2011 ; 118 (5) : 1395-1401.
PubMed
24) Greinacher A. Me or not me? The danger of spontaneity. Blood 2014 ; 123 (23) : 3536-3538.
 
25) Okata T, Miyata S, Miyashita F, et al. Spontaneous heparin-induced thrombocytopenia syndrome without any proximate heparin exposure, infection, or inflammatory condition : Atypical clinical features with heparin-dependent platelet activating antibodies. Platelets 2014 : 1-6.
PubMed
26) Greinacher A, Kohlmann T, Strobel U, et al. The temporal profile of the anti-PF4/heparin immune response. Blood 2009 ; 113 (20) : 4970-4976.
PubMed
27) Warkentin TE, Kelton JG. A 14-year study of heparininduced thrombocytopenia. Am J Med 1996 ; 101 (5) : 502-507.
PubMed
28) Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparininduced thrombocytopenia. Am J Med 1999 ; 106 (6) : 629-635.
PubMed
29) Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005 ; 94 (1) : 132-135.
PubMed
30) Warkentin TE, Kelton JG. Delayed-onset heparininduced thrombocytopenia and thrombosis. Ann Intern Med 2001 ; 135 (7) : 502-506.
PubMed
31) Warkentin TE, Bernstein RA. Delayed-onset heparininduced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin. N Engl J Med 2003 ; 348 (11) : 1067-1069.
PubMed
32) Linkins LA, Warkentin TE. Heparin-induced thrombocytopenia : real-world issues. Semin Thromb Hemost 2011 ; 37 (6) : 653-663.
PubMed
33) Maeda T, Noguchi T, Saito S, et al. Impact of heparininduced thrombocytopenia on acute coronary artery thrombosis in patients undergoing PCI. Thromb Haemost 2014 ; 112 (3) : 624-626.
PubMed
34) Warkentin TE, Roberts RS, Hirsh J, et al. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome : a nested cohort study. Chest 2005 ; 127 (5) : 1857-1861.
PubMed
35) Pouplard C, May MA, Regina S, et al. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol 2005 ; 128 (6) : 837-841.
PubMed
36) Warkentin TE, Linkins LA. Non-necrotizing heparininduced skin lesions and the 4T's score. J Thromb Haemost 2010 ; 8 (7) : 1483-1485.
 
37) Pouplard C, Gueret P, Fouassier M, et al. Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2007 ; 5 (7) : 1373-1379.
PubMed
38) Warkentin TE, Linkins LA. Immunoassays are not created equal. J Thromb Haemost 2009 ; 7 (8) : 1256-1259.
 
39) Warkentin TE, Sheppard JA, Horsewood P, et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000 ; 96 (5) : 1703-1708.
PubMed
40) Greinacher A, Juhl D, Strobel U, et al. Heparin-induced thrombocytopenia : a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007 ; 5 (8) : 1666-1673.
PubMed
41) Greinacher A, Ittermann T, Bagemuhl J, et al. Heparin-induced thrombocytopenia : towards standardization of platelet factor 4/heparin antigen tests. J Thromb Haemost 2010 ; 8 (9) : 2025-2031.
PubMed
42) Kawano H, Yamamoto H, Miyata S, et al. Prospective multicentre cohort study of heparin-induced thrombocytopenia in acute ischaemic stroke patients. Br J Haematol 2011 ; 154 (3) : 378-386.
PubMed
43) Greinacher A, Eichler P, Lubenow N, et al. Heparininduced thrombocytopenia with thromboembolic complications : meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000 ; 96 (3) : 846-851.
PubMed
44) Warkentin TE, Elavathil LJ, Hayward CP, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997 ; 127 (9) : 804-812.
PubMed
P.229 掲載の参考文献
1) Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and out come criteria in immune thrombocytopenic purpura of adults and children : report from an international working group. Blood 2009 ; 113 : 2386-2393.
 
2) Kurata Y, Fujimura K, Kuwana M, et al. Epidemiology of primary immune thrombocytopenia in children and adults in Japan : a population-based study and literature review. Int J Hematol 2011 ; 93 : 329-335.
PubMed
3) McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol 2000 ; 37 : 239-248.
PubMed
4) McMillan R, Wang L, Tomer A, et al, Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult chronic ITP patients. Blood 2004 ; 103 : 1364-1369.
PubMed
5) Kuwana M, Okazaki Y, Kajihara M, et al. Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus : relationship to thrombocytopenia with megakaryocytic hypoplasia. Arthritis Rheum 2002 ; 46 : 2148-2159.
 
6) Kelton JG, Murphy WG, Lucarelli A, et al. A prospective comparison of four techniques for measuring platelet-associated IgG. Br J Haematol 1989 ; 71 : 97-105.
PubMed
7) George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura : a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996 ; 88 : 3-40.
PubMed
8) Brighton TA, Evans S, Castalidi PA, et al. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood 1996 ; 88 : 194-201.
 
9) Kuwana M, Okazaki Y, Kaburaki J, et al. Detection of circulating B cells secreting platelet-specific autoantibody is useful in the diagnosis of autoimmune thrombocytopenia Am J Med 2003 ; 114 : 322-325.
PubMed
10) Kurata Y, Hayashi S, Kiyoi T, et al. Diagnostic value of tests for reticulated platelets, plasma glycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia. Am J Clin Pathol 2001 ; 115 : 656-664.
PubMed
11) Kosugi S, Kurata Y, Tomiyama Y, et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996 ; 93 : 704-706.
PubMed
12) Kuwana M, Kurata Y, Fujimura K, et al. Preliminary laboratory-based diagnostic criteria for immune thrombocytopenic purpura : Evaluation by multi-center prospective study. J Thromb Haemost 2006 ; 4 : 1936-1943.
PubMed
13) Cohen YC, Djulbegovic B, Shamai-Lubovitz O, et al. The bleeding risk and natural history of ITP in patients with persistent low platelet counts. Arch Intern Med 2000 ; 160 : 1630-1638.
PubMed
14) Portielje JE, Westendorp RG, Kluin-Nelemans HC, et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001 ; 97 : 2549-2554.
PubMed
15) McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 2004 ; 104 : 956-960.
PubMed
16) George JN. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 2006 ; 4 : 1664-1672.
PubMed
17) 藤村欣吾, 宮川義隆, 倉田義之, 他. 成人特発性血小板減少性紫斑病治療の参照ガイド2012年版. 臨床血液 2012 ; 53 : 433-442.
 
18) Gasbarrini A, Franceschi F, Tartaglione R, et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998 ; 352 : 878.
PubMed
19) Franchini M, Vesccovi PP, Garofano M, et al. Helicobacter pylori-associated idiopathic thrombocytopenic purpura : a narrative review. Semin Thromb Hemost 2012 ; 38 : 463-468.
 
20) Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura : a systematic review. Blood 2009 ; 113 : 1231-1240.
PubMed
21) Kuwana M. Helicobacter pylori-associated immune thrombocytopenia : clinical features and pathogenic mechanisms. World J Gastroenterol 2014 ; 20 : 714-723.
PubMed
22) Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007 ; 357 : 2237-2247.
PubMed
23) Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura : a double-blind randomised controlled trial. Lancet 2008 ; 371 : 395-403.
PubMed
24) Amold DM, Dentali F, Crowther MA, et al. Systematic review : efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007 ; 146 : 25-33.
 
25) Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura-results of a prospective multicenter phase 2 study. Blood 2008 ; 112 : 999-1004.
PubMed
26) Bussel JB, Pham LC. Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura : review of the literature. Vox Sung 1987 ; 52 : 206-211.
 
27) Fujimura K, Harada Y, Fujimoto T, et al. Nationwide study of idiopathic thrombocytopenic purpura in pregnant women and the clinical influence on neonates. Int J Hematol 2002 ; 75 : 162-168.
 
28) 宮川義隆, 柏木浩和, 高蓋寿朗, 他. 妊娠合併特発性血小板減少性紫斑病診療の参照ガイド. 臨床血液 2014 ; 55 : 934-947.
 
P.236 掲載の参考文献
1) Muta T, Iwanaga S. The role of hemolymph coagulation in innate immunity. Curr Opin Immunol 1996 ; 8 (1) : 41-47.
PubMed
2) McDonald B, Urrutia R, Yipp BG, et al. Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe 2012 ; 12 (3) : 324-333.
PubMed
3) Wong CH, Jenne CN, Petri B, et al. Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance. Nat Immunol 2013 ; 14 (8) : 785-792.
PubMed
4) Vieira-de-Abreu A, Campbell RA, Weyrich AS, et al. Platelets : versatile effector cells in hemostasis, inflammation, and the immune continuum. Sem Immunopathol 2012 ; 34 (1) : 5-30.
 
5) Gross AK, Dunn SP, Feola DJ, et al. Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolysis 2013 ; 35 (2) : 147-154.
 
6) Winning J, Reichel J, Eisenhut Y, et al. Anti-platelet drugs and outcome in severe infection : clinical impact and underlying mechanisms. Platelets 2009 ; 20 (1) : 50-57.
PubMed
7) Winning J, Neumann J, Kohl M, et al. Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med 2010 ; 38 (1) : 32-37.
 
8) Phillipson M, Kubes P. The neutrophil in vascular inflammation. Nat Med 2011 ; 17 (11) : 1381-1390.
PubMed
9) Proebstl D, Voisin MB, Woodfin A, et al. Pericytes support neutrophil subendothelial cell crawling and breaching of venular walls in vivo. The Journal of experimental medicine 2012 ; 209 (6) : 1219-1234.
PubMed
10) Sreeramkumar V, Adrover JM, Ballesteros I, et al. Neutrophils scan for activated platelets to initiate inflammation. Science 2014 ; 346 (6214) : 1234-1238.
PubMed
11) Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007 ; 13 (4) : 463-469.
PubMed
12) Caudrillier A, Kessenbrock K, Gilliss BM, et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest 2012 ; 122 (7) : 2661-2671.
PubMed
13) Mantovani A, Garlanda C. Platelet-macrophage partnership in innate immunity and inflammation. Nat Immunol 2013 ; 14 (8) : 768-770.
PubMed
14) Verschoor A, Neuenhahn M, Navarini AA, et al. A platelet-mediated system for shuttling blood-borne bacteria to CD8 α + dendritic cells depends on glycoprotein GPIb and complement C3. Nat Immunol 2011 ; 12 (12) : 1194-1201.
 
15) Elzey BD, Tian J, Jensen RJ, et al. Platelet-Mediated Modulation of Adaptive Immunity. Immunity ; 19 (1) : 9-19.
 
16) Speth C, Loffler J, Krappmann S, et al. Platelets as immune cells in infectious diseases. Future Microbiol 2013 ; 8 (11) : 1431-1451.
PubMed
17) Ito T. PAMPs and DAMPs as triggers for DIC. J Intensive Care 2014 ; 2 (1) : 65.
PubMed
18) Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001 ; 345 (6) : 408-416.
PubMed
19) Kraemer BF, Campbell RA, Schwertz H, et al. Bacteria differentially induce degradation of Bcl-xL, a survival protein, by human platelets. Blood 2012 ; 120 (25) : 5014-5020.
PubMed
20) Jackson SP, Schoenwaelder SM. Procoagulant platelets : are they necrotic? Blood 2010 ; 116 (12) : 2011-2018.
PubMed
21) Stephan F, Thioliere B, Verdy E, et al. Role of hemophagocytic histiocytosis in the etiology of thrombocytopenia in patients with sepsis syndrome or septic shock. Clin Infect Dis 1997 ; 25 (5) : 1159-1164.
PubMed
22) Grewal PK, Uchiyama S, Ditto D, et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med 2008 ; 14 (6) : 648-655.
PubMed
23) Grozovsky R, Begonja AJ, Liu K, et al. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med 2014 ; doi : 10.1038/nm.3770.
 
24) Andonegui G, Kerfoot SM, McNagny K, et al. Platelets express functional Toll-like receptor-4. Blood 2005 ; 106 (7) : 2417-2423.
PubMed
P.241 掲載の参考文献
1) Brinkmann V, Laube B, Abu Abed U, et al. Neutrophil extracellular traps : how to generate and visualize them. J Vis Exp 2010 ; 36 : e1724.
 
2) Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004 ; 303 (5663) : 1532-1535.
PubMed
3) Brinkmann V, Zychlinsky A. Beneficial suicide : why neutrophils die to make NETs. Nat Rev Microbiol. 2007 ; 5 (8) : 577-582.
PubMed
4) Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013 ; 13 (3) : 159-175.
PubMed
5) McDonald B, Urrutia R, Yipp BG, et al. Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe. 2012 ; 12 (3) : 324-333.
PubMed
6) Papayannopoulos V, Zychlinsky A. NETs : a new strategy for using old weapons. Trends Immunol. 2009 ; 30 (11) : 513-521.
PubMed
7) Yipp BG, Kubes P. NETosis : how vital is it? Blood. 2013 ; 122 (16) : 2784-2794.
PubMed
8) Mori Y, Yamaguchi M, Terao Y, et al. α -Enolase of Streptococcus pneumoniae induces formation of neutrophil extracellular traps. J Biol Chem. 2012 ; 287 (13) : 10472-10481.
 
9) Papayannopoulos V, Metzler KD, Hakkim A, et al. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol. 2010 ; 191 (3) : 677-691.
PubMed
10) Yost CC, Cody MJ, Harris ES, et al. Impaired neutrophil extracellular trap (NET) formation : a novel innate immune deficiency of human neonates. Blood. 2009 ; 113 (25) : 6419-6427.
PubMed
11) Byrd AS, O' Brien XM, Johnson CM, et al. An extracellular matrix-based mechanism of rapid neutrophil extracellular trap formation in response to Candida albicans. J Immunol. 2013 ; 190 (8) : 4136-4148.
PubMed
12) Hemmers S, Teijaro JR, Arandjelovic S, et al. PAD4-mediated neutrophil extracellular trap formation is not required for immunity against influenza infection. PLoS One. 2011 ; 6 (7) : e22043.
 
13) Saitoh T, Komano J, Saitoh Y, et al. Neutrophil extracellular traps mediate a host defense response to human immunodeficiency virus-1. Cell Host Microbe. 2012 ; 12 (1) : 109-116.
PubMed
14) Douda DN, Jackson R, Grasemann H, et al. Innate immune collectin surfactant protein D simultaneously binds both neutrophil extracellular traps and carbohydrate ligands and promotes bacterial trapping. J Immunol. 2011 ; 187 (4) : 1856-1865.
PubMed
15) Xu J, Zhang X, Monestier M, et al. Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. J Immunol. 2011 ; 187 (5) : 2626-2631.
 
16) Saffarzadeh M, Juenemann C, Queisser MA, et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death : a predominant role of histones. PLoS One. 2012 ; 7 (2) : e32366.
 
17) Ammollo CT, Semeraro F, Xu J, et al. Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation. J Thromb Haemost. 2011 ; 9 (9) : 1795-1803.
PubMed
18) Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010 ; 107 (36) : 15880-15885.
PubMed
19) Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. Nat Med 2009 ; 15 (11) : 1318-1321.
 
20) Fuchs TA, Bhandari AA, Wagner DD. Histones induce rapid and profound thrombocytopenia in mice. Blood. 2011 ; 118 (13) : 3708-3714.
PubMed
21) Villanueva E, Yalavarthi S, Berthier CC, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol. 2011 ; 187 (1) : 538-552.
PubMed
22) Kessenbrock K, Krumbholz M, Schonermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009 ; 15 (6) : 623-625.
PubMed
23) Hakkim A, Furnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A. 2010 ; 107 (21) : 9813-9818.
PubMed
24) Sur Chowdhury C, Giaglis S, Walker UA, et al. Enhanced neutrophil extracellular trap generation in rheumatoid arthritis : analysis of underlying signal transduction pathways and potential diagnostic utility. Arthritis Res Ther 2014 ; 16 (3) : R122.
PubMed
25) Demers M, Krause DS, Schatzberg D, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A. 2012 ; 109 (32) : 13076-13081.
PubMed
26) Caudrillier A, Kessenbrock K, Gilliss BM, et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest. 2012 ; 122 (7) : 2661-2671.
PubMed
27) Lee WL, Grinstein S. Immunology. The tangled webs that neutrophils weave. Science 2004 ; 303 (5663) : 1477-1478.
PubMed
28) Schauer C, Janko C, Munoz LE, et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med 2014 ; 20 (5) : 511-517.
PubMed

書評

最近チェックした商品履歴

Loading...